World Journal of Clinical Oncology

Submit a Manuscript: https://www.f6publishing.com

World J Clin Oncol 2024 January 24; 15(1): 62-88

DOI: 10.5306/wico.v15.i1.62

ISSN 2218-4333 (online)

ORIGINAL ARTICLE

Clinical and Translational Research

Identification of the key genes and mechanisms associated with transcatheter arterial chemoembolisation refractoriness in hepatocellular carcinoma

Jie-Zhuang Huang, Jian-Di Li, Gang Chen, Rong-Quan He

Specialty type: Biochemistry and molecular biology

Provenance and peer review: Unsolicited article; Externally peer reviewed

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0 Grade B (Very good): B Grade C (Good): 0 Grade D (Fair): 0 Grade E (Poor): 0

P-Reviewer: Lykoudis PM, United Kingdom

Received: October 23, 2023 Peer-review started: October 23, 2023 First decision: November 23, 2023 Revised: December 12, 2023 Accepted: December 28, 2023 Article in press: December 28, 2023 Published online: January 24, 2024



Jie-Zhuang Huang, Rong-Quan He, Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China

Jian-Di Li, Gang Chen, Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China

Corresponding author: Rong-Quan He, MD, PhD, Doctor, Researcher, Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. herongquan@gxmu.edu.cn

Abstract

BACKGROUND

Transcatheter arterial embolisation (TACE) is the primary treatment for intermediate-stage hepatocellular carcinoma (HCC) patients while some HCC cases have shown resistance to TACE.

AIM

To investigate the key genes and potential mechanisms correlated with TACE refractoriness in HCC.

METHODS

The microarray datasets of TACE-treated HCC tissues, HCC and non-HCC tissues were collected by searching multiple public databases. The respective differentially expressed genes (DEGs) were attained via limma R package. Weighted gene co-expression network analysis was employed for identifying the significant modules related to TACE non-response. TACE refractoriness-related genes were obtained by intersecting up-regulated TACE-associated and HCC-associated DEGs together with the genes in significant modules related to TACE nonresponse. The key genes expression in the above two pairs of samples was compared respectively via Wilcoxon tests and standard mean differences model. The prognostic value of the key genes was evaluated by Kaplan-Meier curve. Multivariate analysis was utilised to investigate the independent prognostic factor in key genes. Single-cell RNA (scRNA) sequencing analysis was conducted to explore the cell types in HCC. TACE refractoriness-related genes activity was



calculated via AUCell packages. The CellChat R package was used for the investigation of the cell-cell communication between the identified cell types.

RESULTS

HCC tissues of TACE non-responders (n = 66) and TACE responders (n = 81), HCC (n = 3941) and non-HCC (n = 66) 3443) tissues were obtained. The five key genes, DLG associated protein 5 (DLGAP5), Kinesin family member 20A (KIF20A), Assembly factor for spindle microtubules (ASPM), Kinesin family member 11 (KIF11) and TPX2 microtubule nucleation factor (TPX2) in TACE refractoriness-related genes, were identified. The five key genes were all up-regulated in the TACE non-responders group and the HCC group. High expression of the five key genes predicted poor prognosis in HCC. Among the key genes, TPX2 was an independent prognostic factor. Four cell types, hepatocytes, embryonic stem cells, T cells and B cells, were identified in the HCC tissues. The TACE refractoriness-related genes expressed primarily in hepatocytes and embryonic stem cells. Hepatocytes, as the providers of ligands, had the strongest interaction with embryonic stem cells that provided receptors.

CONCLUSION

Five key genes (DLGAP5, KIF20A, ASPM, KIF11 and TPX2) were identified as promoting refractory TACE. Hepatocytes and embryonic stem cells were likely to boost TACE refractoriness.

Key Words: Hepatocellular carcinoma; Transcatheter arterial embolisation refractoriness; Weighted gene co-expression network analysis; Single-cell RNA sequencing; AUCell; CellChat

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This is a study that explored the key genes and mechanisms related to transcatheter arterial chemoembolisation (TACE) refractoriness in hepatocellular carcinoma. Through the combination of tissue microarrays and RNA-seq with single-cell RNA sequencing, the TACE refractoriness-related genes were identified and five key genes (DLGAP5, KIF20A, ASPM, KIF11 and TPX2) associated with TACE refractoriness were revealed. The TACE refractoriness-related genes were found to mainly express in hepatocytes and embryonic stem cells. Hepatocytes providing ligands had the strongest interaction with embryonic stem cells as receptors providers.

Citation: Huang JZ, Li JD, Chen G, He RQ. Identification of the key genes and mechanisms associated with transcatheter arterial chemoembolisation refractoriness in hepatocellular carcinoma. World J Clin Oncol 2024; 15(1): 62-88 URL: https://www.wjgnet.com/2218-4333/full/v15/i1/62.htm DOI: https://dx.doi.org/10.5306/wjco.v15.i1.62

INTRODUCTION

Hepatocellular carcinoma (HCC) is a major primary liver tumour, accounting for more than 90% of primary liver tumour cases[1]. HCC is currently the fifth most common cancer worldwide and the second leading cause of cancer death in men, with the five-year survival rate of 18% second only to pancreatic cancer[1]. The complex pathogenesis of HCC and its various risk factors like chronic hepatitis B virus infection and alcohol abuse lead to the increasing incidence of HCC[2,3]. A retrospective study showed that the incidence of HCC increased markedly in America from 1975 to 2016[4]. It is worth noting that HCC is generally diagnosed in its advance stage^[5]. The appearance of symptoms stage means the rapid progress of HCC with the poor therapeutic effect and slim survival^[6].

Transcatheter arterial embolisation (TACE) is a strategy in which catheters, with the support of various embolisation drugs, are placed in the large arteries, typically the femoral arteries, to block the tumour's blood supply [7,8]. The selection of the treatment is based on the Barcelona Clinic Liver Cancer staging system, which was created according to the number size of the HCC and the performance of the patient[9]. TACE is a standard therapy for intermediate-stage HCC patients^[10]. Currently, surgical treatment, liver transplantation and ablation are available for early-HCC patients and contribute to a high survival rate[8,11]. However, metastatic disease may be a barrier to surgical therapy[12]. Local ablation is regarded as a safer alternative to surgery, but it is also not suitable for patients who have tumours in the subcapsular or domed position or near the main bile duct, large blood vessels or the intestine[13]. Patients who cannot benefit from the above treatments despite the early stage of the disease may be candidates for TACE^[14]. Chemotherapy is universally considered the first choice for advanced HCC when there is a low pharmaceutical response or the formation of portal vein tumour thrombosis^[15]. In clinical practice, multiple combinations of liver-directed therapies (LDT) pave the way for the curative treatment [16], and TACE is still the most widely used as an LDT for locally advanced HCC patients [17]. Therefore, TACE is an important method for treating HCC at all stages.

Unfortunately, some investigations have shown that a load of HCC patients did not respond to TACE, which reduces the efficacy of the systematic therapy significantly [18]. One recent study employed a cohort of HCC patients after TACE treatment, and a series of vitro experiments revealed that pyruvate kinase M1/2 was highly expressed, which may

WJCO https://www.wjgnet.com

Huang JZ et al. Key genes associated with TACE refractoriness




Figure 1 The flow chart of the present study. HCC: Hepatocellular carcinoma; DEGs: Differentially expressed genes; TACE: Transcatheter arterial chemoembolisation; WGCNA analysis: Weighted gene co-expression network analysis.

promote HCC tolerance to TACE through glycolysis dysregulation[19], and was associated with a low survival rate in TACE non-response HCC patients. Additionally, another study found that the low expression of miRNA-125b induced an HCC tolerance to TACE through a transcriptome analysis of 680 HCC patients [20]. However, HCC is featured in the high heterogeneity of genetic drivers leading to therapeutic susceptibility [21]. Therefore, individual genes heterogeneity requires the exploration of other potential factors through systematic measures.

In this study, we aimed to identify the key genes of TACE refractoriness in HCC. Additionally, the potential mechanisms of TACE refractoriness in HCC were explored. Finally, potential therapeutic drugs against TACE refractoriness in HCC were discovered. The flow chart of this study is shown in Figure 1.

MATERIALS AND METHODS

Data collection and processing

We retrieved the datasets including TACE non-responders and TACE responders from the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), International Cancer Genome Consortium and ArrayExpress databases, with the query formulation 'Hepatocellular carcinoma AND Transcatheter arterial embolisation'. The datasets included were required to belong to Homo sapiens and contained HCC tissues from TACE non-responders and TACE responders who had not received any prior treatment. Simultaneously, we collected HCC and its control samples from the TCGA, GEO, Genotype-tissue Expression (GTEx) and ArrayExpress databases with keywords 'hepatocellular carcinoma' based on the following criteria: (1) The matrix must be Homo sapiens; (2) the data sets should include HCC and normal liver tissues or one of the above groups and can be merged; and (3) the collected samples should not be influenced by any chemicals or physical treatment. Subsequently, the profiles of all of the screened datasets downloaded from the above database were annotated according to the platform annotation files and then conducted by $log_2(x+1)$ conversion. To integrate the expression matrix from the same platforms or append the lack of normal liver tissue samples in some matrices, the R software (Version 3.6.2) was used to merge and normalise datasets with different sequencing and background through limma and surrogate variable analysis (sva) packages.

The screening of differentially expressed genes

The *limma* package was applied to identify the differentially expressed genes (DEGs). The DEGs between TACE nonresponders and TACE responders (TACE-associated DEGs) had to meet the requirement of P value < 0.05 and $|\log_2$



Raishidena® WJCO https://www.wjgnet.com

(Foldchange) | > 0.5. The DEGs between HCC and non-HCC tissues (HCC-associated DEGs) from the datasets were integrated by calculating the standardised mean difference (SMD). DEGs with P < 0.05 and |SMD| > 0 were recorded as the DEGs in HCC.

Weighted gene co-expression network analysis

Weighted gene co-expression network analysis (WGCNA) is a systematic biological method for calculating the correlation among genes for finding gene clusters (modules) and connecting gene modules with external sample traits using eigengene network methodology^[22]. In this study, we utilised WGCNA analysis to identify more reliable hub genes associated with TACE refractoriness in HCC.

The co-expression network construction

WGCNA R package was utilised to construct the co-expression network using the expression profile of the TACEassociated DEGs in GSE104580. Firstly, Pearson's correlation matrix and average linkage methods were both used for all pair-wise genes. Secondly, an adjacency matrix was established to calculate the correlation value. The soft threshold was used to emphasise the correlation between two genes and eliminate weak correlations. Thirdly, adjacency was transformed into a topological overlap matrix (TOM) to measure the similarity of the nodes by comparing the weighted correlation between each of the nodes. At the same time, the corresponding dissimilarity (1-TOM) was calculated.

Identification of the clinically significant modules

Module eigengene was the first principal component of the module and was defined as the expression file of the whole genes in the module. The correlation coefficient between module eigengene and the clinical trait, namely the reactivity to TACE, was calculated to identify the clinically significant module. Module membership was regarded as the correlation between the genes and the module eigengene and was used to evaluate whether the genes belonged to the module or not. Additionally, gene significance was defined as the mediated *P* in the linear regression between expression and clinical traits. In addition, module significance was the average absolute gene significance of whole genes in the module. Finally, the modules with the top-two correlation coefficients between module eigengene and clinical status TACE nonresponders were selected as the clinically significant modules for further analysis.

The screening of key genes in the protein–protein interaction network

The up-regulated genes in TACE-associated DEGs, up-regulated HCC-associated DEGs and the genes in the clinically significant modules were intersected and their shared genes were considered as TACE refractoriness-related genes. TACE refractoriness-related genes were utilised for protein-protein interaction (PPI) network construction via STRING database. Then, the key genes were identified using the Maximal Clique Centrality (MCC) method of cytoHubba plugin in Cytoscape software (Version 3.7.2). MCC algorithm is a method of scoring each protein in the PPI network. A higher score means the protein is associated with more proteins in the network.

The validation of the key genes in expression and prognosis

The mRNA expression level of the key genes between TACE non-responders and TACE responders was compared through Wilcoxon tests. Then, to verify that the key genes were differentially expressed in HCC, SMD model and a 95% confidence interval (95%CI) were carried out using Meta R packages and STATA 12.0 by integrating the datasets containing HCC and non-HCC tissues. A random-effect model or fixed-effect model was selected in the light of the I² test and Chi-square test. The random-effect model was chosen when there was high heterogeneity ($l^2 > 50\%$ or P < 0.05). Otherwise, the fixed-effect model was chosen. Sensibility analysis was conducted to detect the high heterogeneous datasets. The protein expression of key genes in HCC tissues was compared to that in non-HCC tissues by browsing The Human Protein Atlas (THPA) database. We then gathered the clinical information of the HCC tissues in the datasets. The clinical information was required to include survival status and survival time, and only the clinical information in TCGA datasets was eligible. To identify the independent prognostic factors in the key genes, multivariate analysis was used. For survival analysis, the optimum cut-off for division into high expression and low expression group was determined by running Survminer and Survival packages and the hazard ratio (HR) was calculated by Cox-proportional hazards regression model. Finally, the Kaplan-Meier was visualised using the Survival package.

Gene sets enrichment analysis

TACE refractoriness-related genes were utilised in gene ontology (GO) annotation analysis, Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway using the clusterProfiler R package and Reactome pathway using Reactome pathway database. The terms with P < 0.05 and FDR < 0.25 were considered statistically significant. The top-five GO terms in respect to biological process (BP), cellular component (CC) and molecular function (MF) were investigated. Finally, the KEGG pathways and the top-ten Reactome pathways were visualised.

Single-cell RNA sequencing data pre-processing and cell type identification

To further explore the cell types involved in TACE refractoriness, single-cell RNA sequencing (scRNA-seq) analysis was adopted. The scRNA-seq data were obtained from the GEO database with the search strategy 'ScRNA OR Single Cell AND Hepatocellular Carcinoma'. The samples in the scRNA-seq data had to be HCC samples that were not treated using any chemical or physical factors. The quality control process of the scRNA-seq data was performed with the Seurat R package. Cells with < 500 genes, > 6000 genes or > 20% mitochondrial genes were filtered out. Then, the gene expression matrix was normalised and scaled. Subsequently, the Harmony R package was employed for eliminating batch effect. A



uniform manifold approximation and projection (UMAP) analysis was performed for dimensional reduction. The FindClusters function was able to classify the cells into different clusters with a resolution of 0.5, and the annotation of the cell clusters depended on the SingleR package. The activity of TACE refractoriness-related genes in each cell line was determined using the AUCell R package. Cells expressing more TACE refractoriness-related genes had higher area under-the-curve (AUC) values. The 'AUCell_exploreThresholds' function was used to determine the threshold for identifying TACE refractoriness-related genes' active cells. The AUC score of each cell was then mapped to the UMAP plot embedding using the ggplot2 R package to visualise the active clusters.

Cell–cell communication analysis

CellChat, an open R package, was utilised for the analysis of intercellular communications using scRNA-seq data[23]. After identifying the cell types in the HCC tissues, the CellChat R package (Version 1.1.3) was employed to investigate the number of interactions, the communication strength and the over-expressed ligands and receptors between each identified cell type. The discovery of overexpressed ligand-receptor pairs was based on the data of ligand-receptor pairs related to 'Secreted Signalling' in datasets CellChatDB. The communication probability was calculated by means of the function 'computeCommunProb' in the CellChat R package. Subsequently, the cell-cell communication was predicted and aggregated. The number of interactions was visualised to show integrated communication.

Immune infiltration analysis

To elucidate the correlation between the TACE resistance and tumour microenvironment in the HCC, we conducted immune infiltration analysis based on CIBERSORT and xCell algorithm. The CIBERSORT algorithm is a deconvolution method used, in this case, to process marker gene expression values to estimate the proportion of various types of immune cells[24]. The xCell algorithm was performed for cell-type enrichment analysis from gene expression data of 64 immune and stroma cell types[25]. In this study, the CIBERSORT algorithm assessed the proportions of 22 kinds of immune cells between TACE non-responders and TACE responders. Meanwhile, the relationship between the expression of the five key genes and the 22 kinds of immune cells' infiltration in the HCC samples from TACE non-responders was explored. The xCell algorithm evaluated the immune score, stromal score, microenvironment score and proportions of the cell types of the scRNA-seq analysis. Statistical significance required P < 0.05.

The exploration of potential therapeutic drugs

The pRRophetic R package was adopted to predict the half maximal inhibitory concentration (IC50) of chemotherapeutic agents antagonising HCC in the Genomics of Drug Sensitivity in Cancer database. IC_{50} represented the effectiveness of each kind of chemotherapeutic agent inhibiting specific biological or biochemical functions. The comparison of the IC₅₀s of the TACE non-responders group and the TACE responders group was tested by Wilcoxon signed-rank test.

RESULTS

Data collection and differentially expressed gene screening

The gene expression matrix GSE104580 including HCC samples of 66 TACE non-responders and 81 TACE- responders was obtained from the GEO database. The screening procedure can be seen in Figure 2. Additionally, a total of 3941 HCC and 3443 non-HCC samples were obtained from the TCGA, GEO, GTEx and ArrayExpress databases. The 85 studies that included HCC and non-HCC tissues were collected according to the procedure in Figure 3. The detailed information of the 84 datasets (datasets from TCGA and GTEx databases have been merged as one dataset) are listed in Supplementary Table 1. A total of 619 up-regulated and 648 down-regulated TACE-associated DEGs were screened and visualised (Figure 4A). The expression levels of the 30 top up-regulated and down-regulated DEGs were respectively performed (Figure 4B). In addition, 8676 up-regulated and 7125 down-regulated HCC-associated DEGs were obtained after integrating DEGs from 85 studies.

Constructing the co-expression modules


The expression file of 1267 TACE-associated DEGs and the clinical traits in GSE104580 were used for the WGCNA analysis. The soft-threshold β = 7 with the highest scan-free topology model fit (R^2 = 0.88) and the mean connectivity lower than 100 was set to construct a scan-free network (Figure 5A and B). Subsequently, the adjacency matrix was built and turned into a TOM to establish a gene-clustering dendrogram (Figure 5C). As shown in Figure 5C, each colour in the merge-dynamic row corresponds to a gene module after they were merged based on the cut line 0.25, and, finally, a total of five modules were identified.

The identification of clinically significant modules and the key genes

The clinical traits, namely reactivity to TACE in GSE104580, were combined with the five identified modules to screen for the clinically significant module(s) (Figure 5D). Finally, the blue and grey modules were identified as the clinically significant modules due to having the highest correlation coefficient with the clinical trait TACE non-responders. A total of 195 genes were in the blue and grey modules. After intersecting 619 up-regulated TACE-associated DEGs, 8676 upregulated HCC-associated DEGs and 195 genes in the clinically significant modules, a total of 112 shared genes were identified as TACE refractoriness-related genes for further analysis (Figure 5E). According to the scoring results from the MCC algorithm, the top-five genes had relatively high scores, while the rest had extremely low scores. To ensure




WJCO | https://www.wjgnet.com



DOI: 10.5306/wjco.v15.i1.62 Copyright ©The Author(s) 2024.

Figure 2 Flow chart showing the collection of the transcatheter arterial embolisation-treated hepatocellular carcinoma samples. Finally, one study was included. HCC: Hepatocellular carcinoma; TACE: Transcatheter arterial chemoembolization.



DOI: 10.5306/wjco.v15.i1.62 Copyright ©The Author(s) 2024.

Figure 3 Flow chart of the acquisition of hepatocellular carcinoma and non-hepatocellular carcinoma samples via database. The information from 85 studies is displayed in Supplementary Table 1. HCC: Hepatocellular carcinoma.

reliability and accuracy, we selected the top-five genes as the key genes among the TACE refractoriness-related genes. The five key genes, DLG associated protein 5 (DLGAP5), Kinesin family member 20A (KIF20A), Assembly factor for spindle microtubules (ASPM), Kinesin family member 11 (KIF11) and TPX2 microtubule nucleation factor (TPX2), were identified using the MCC methods in the CytoHubb plugin contained in Cytoscape software (Figure 6A).

The expression validation of key genes in TACE-treated HCC samples

To ascertain the key genes' differential expression in the HCC samples of the TACE non-responders and TACE responders, the mRNA expression of DLGAP5, KIF20A, ASPM, KIF11 and TPX2 was analysed. The results showed that



Raishideng® WJCO | https://www.wjgnet.com




Figure 4 Differentially expressed genes screening. A: The screening of differentially expressed genes (DEGs) between transcatheter arterial embolisation (TACE) non-responders and TACE responders (TACE-associated DEGs) in GSE104580. B: The expression level of the top-30 up-regulated and down-regulated TACE-associated DEGs.

the five key genes were all more highly expressed in the TACE non-responders group compared with TACE responders group (Figure 6B).

The expression validation of key genes in HCC via integrated data

After integrating all enrolled data including HCC and non-HCC tissues, we found that the SMD and 95%CI of the five key genes under random effects were as follows: DLGAP5 (SMD: 1.54, 95%CI: 1.38–1.90), KIF20A (SMD: 1.88, 95%CI: 1.63–2.13), ASPM (SMD: 2.00, 95%CI: 1.74–2.25), KIF11 (SMD: 1.45, 95%CI: 1.20–1.70) and TPX2 (SMD: 1.64, 95%CI: 1.43–1.85) (Figure 7). These indicated that the expression level of the five key genes was remarkably higher in the HCC than in the non-HCC tissues. The protein expression of key genes DLGAP5, KIF20A, KIF11 and TPX2 in the HCC tissues was higher than in the non-HCC tissues (Figure 8). The IHC resource for protein expression of ASPM was lack in THPA database.

The prognostic value of key genes

TPX2 was considered an independent prognostic factor in HCC *via* multivariate analysis (Figure 9A). The results showed that a high expression of the key genes was correlated with a low overall survival. To verify the key genes participating in HCC poor prognosis, the survival curves are shown in Figure 9B–F. In addition, HR was as follows: DLGAP5 (HR: 2.197, P < 0.0001), KIF20A (HR: 3.940, P < 0.0001), ASPM (HR: 2.702, P = 0.0011), KIF11 (HR: 4.021, P < 0.0001) and TPX2 (HR: 3.287, P < 0.0001).

GO enrichment and pathway analysis

For BP, the 112 TACE refractoriness-related genes were mainly enriched in nuclear division, organelle fission, mitotic nuclear division, chromosome segregation and mitotic sister chromatid segregation. CC involved spindle, chromosomal region, chromosome, centromeric region, microtubule and midbody. As for MF, these TACE refractoriness-related genes were associated with microtubule binding, tubulin binding, microtubule motor activity, cytoskeletal motor activity and peptidase regulator activity (Figure 10A). With regards to the pathways, these TACE refractoriness-related genes were mainly active in cell cycle pathways in the KEGG pathway enrichment analysis, and the relevant reactome pathways are shown in Figure 10B.

Zaishideng® WJCO | https://www.wjgnet.com







Figure 5 Weighted gene co-expression network analysis and identification of transcatheter arterial embolisation refractoriness-related genes. A: The scale-free index for various soft-threshold powers; B: Analysis of the mean connectivity for various soft-threshold powers; C: Gene clustering dendrogram, with dissimilarity based on topological overlap, together with assigned module colours; D: Module-trait association. Blue and grey modules were


Caishideng® WJCO | https://www.wjgnet.com


identified as the clinically significant modules due to their highest coefficient correlations; E: The identification of 112 TACE refractoriness-associated genes. TACE: Transcatheter arterial embolisation.











DOI: 10.5306/wjco.v15.i1.62 Copyright ©The Author(s) 2024.

Figure 6 The identification and mRNA expression of five key genes in transcatheter arterial embolisation treated hepatocellular carcinoma. A: Five key genes were identified using Maximal Clique Centrality method of the cytoHubba plugin. B: The mRNA expression level of the five key genes in hepatocellular carcinoma samples of transcatheter arterial embolisation (TACE) non-responders and TACE responders. DLGAP5: DLG-associated protein 5; KIF20A: Kinesin family member 20A; ASPM: Assembly factor for spindle microtubules; KIF11: Kinesin family member 11; TPX2: TPX2 microtubule nucleation factor.

Raishideng® WJCO | https://www.wjgnet.com

Α			DLGA	P5			
Study	Experime Total Mean S		Control Mean SD	Standardised Mean difference	SMD	95%CI	Weight
E_MTAB_4171	15 8.71 1.04	24 15	6.31 1.1043	ļ.	2.18	1.25; 3.11]	3.0%
E_MTAB_8887	23 4.63 0.75	18 17	3.92 0.8809	+		0.21; 1.52]	3.7%
GPL10558	523 5.42 0.36	37 403	4.91 0.1389	+		1.61; 1.91]	4.8%
GPL11154	163 1.14 0.82	94 140	0.28 0.3909	•		1.04; 1.54]	4.7%
GPL14951	93 8.66 1.45	14 18	8.05 1.0281			-0.07; 0.95]	4.1%
GPL16043	25 1.70 1.3	04 25	1.58 1.5070	E		-0.47; 0.64]	
GPL16791	79 4.24 1.14	09 78	2.30 0.8821		1.90 r	1.52; 2.28]	4.4%
GPL21047	10 3.02 0.17	25 10	2.99 0.0733			-0.67; 1.08]	3.1%
GPL5175	48 2.77 0.18	70 48	2.23 0.0851	+	3.65 r	2.99; 4.32]	3.7%
GPL570	844 3.77 0.68	76 528	2.63 0.3608		1.96	1.82; 2.09]	4.8%
GPL571	96 2.49 0.18		2.36 0.0538			0.74; 1.30]	4.6%
GPL6244	66 3.18 0.29		2.80 0.1204	+	1.75	1.36; 2.14]	4.4%
GPL6480	83 2.90 0.36		2.47 0.3228		1.25 [0.91; 1.58]	4.5%
GPL9052	60 1.41 1.18		2.33 0.9821	+	3.42 [2.85; 3.99]	4.0%
GSE115018_GPL20115	12 -0.72 0.79		1.92 0.1861			1.00; 3.04]	2.8%
GSE124535_GPL20795	35 1.50 0.94		0.27 0.3095	+		1.18; 2.29]	4.0%
GSE125469_GPL20301	3 4.14 0.57		0.38 0.1631	÷ • • • • • • • • • • • • • • • • • • •		0.06; 14.25]	0.1%
GSE166163_GPL23126	3 4.01 2.02		4.22 2.8167	+		-1.67; 1.54]	
GSE33294_GPL10999	3 1.91 0.18		0.14 0.0706	+		0.23; 20.38]	0.1%
GSE46408_GPL4133	6 10.07 1.19		5.06 1.1500		3.95 [1.72; 6.19]	1.0%
GSE46444_GPL13369	88 7.84 1.57		6.94 1.1699	+		0.26; 0.98]	4.5%
GSE50579_GPL14550	67 2.90 0.44		1.79 0.2500			1.80; 3.38]	3.4%
GSE55048_GPL9115	4 1.33 0.52		0.07 0.0130			0.50; 5.42]	0.9%
GSE56545_GPL15433	21 2.80 0.2		1.51 0.8302		2.06 [1.30; 2.82]	3.4%
GSE57555_GPL16699	5 -0.18 0.0		0.15 0.0355	독실		-2.15; 0.50]	
GSE60502_GPL96	18 7.88 1.03		6.20 0.2764	L. L.	2.17[1.33; 3.02]	3.2%
GSE63898_GPL13667	228 4.85 0.9		3.96 0.1485	•	1.27[1.05; 1.49]	4.7%
GSE67764_GPL17077	3 0.18 1.25		1.86 0.5240	1 <u></u>	2.26	0.29; 4.22]	1.3%
GSE76311_GPL17586	62 2.59 0.20		2.24 0.0298	2	-	1.93; 2.87]	4.2%
TCGA_GTEx_liver	371 2.11 0.98	51 276	0.35 0.4823	1	-	1.97; 2.37]	4.8%
Random effects model	3057	2307		 		[1.38; 1.90	

-20

KIF20A

-10

0

10

20

Heterogeneity: $I^2 = 91\%$, $\tau^2 = 0.3562$, P < 0.01

В

D										
		Experi	menta	l I	Control	S	tandardised			
Study	Total	Mean	SD	Total	Mean SD	Me	ean difference	SMD	95%CI	Weight
E MTAB 4171	15	8.19	1.1756	15	5.67 0.9525		1 +	2.29	[1.34; 3.24	1 2.3%
E_MTAB_8887	23		1.1759		3.28 0.8237		-	0.90	0.24; 1.57	
GPL10558	523	5.63 (0.3737	403	5.05 0.1581		•	1.93	[1.77; 2.09	
GPL11154	163	1.40 (0.8682	140	0.32 0.3853		+	1.55	[1.29; 1.81	
GPL14951	93	8.31	1.1921	18	7.13 1.1734			0.99	[0.46; 1.51] 3.0%
GPL16043	25	1.67	1.7806	25	1.52 2.0684		- Q	0.08	[-0.48; 0.6	3] 3.0%
GPL16791	79	4.53	1.1789	78	2.49 1.0339			1.82	[1.45; 2.20] 3.2%
GPL21047	10	2.74 (0.2943	10	1.87 0.2621			2.96	[1.61; 4.31	.] 1.7%
GPL5175	48	2.94 (0.1607	48	2.45 0.0721			3.91	[3.21; 4.60)] 2.8%
GPL570	844	4.05 (0.6247	528	2.96 0.3707		•	2.01	[1.88; 2.14	F] 3.5%
GPL571	96	2.54 (0.2028	131	2.41 0.0576		+	0.96	[0.68; 1.24	l] 3.3%
GPL6244	66	3.24 (0.3009	75	2.84 0.1271		+	1.76	[1.37; 2.15	5] 3.2%
GPL6480	83	2.84 (0.2959	82	2.43 0.2332		+	1.56	[1.21; 1.91	
GPL6947	104		0.1656		2.79 0.1667			2.29	[1.93; 2.65	
GPL9052	60		1.0384		-1.48 0.7494			4.17	[3.53; 4.82	
GSE114783_GPL15491	10		1.5549		7.78 1.8149		- -	-0.30	[-1.03; 0.4	
GSE115018_GPL20115	12		0.7086		-1.24 1.0917		÷ • •	2.83	[1.64; 4.02	
GSE124535_GPL20795	35		1.0251		0.30 0.4322		÷.	1.72	[1.16; 2.27	
GSE125469_GPL20301	3		0.5284		0.49 0.4521				[-0.05; 10.8	
GSE14520_GPL3921	225		0.2385		2.17 0.0789		•	2.49	[2.24; 2.73	
GSE166163_GPL23126	3		1.8453		3.28 2.2205			-0.11	[-1.72; 1.4	
GSE20140_GPL18461	35		0.7503		7.09 0.3843			2.00	[1.42; 2.59	
GSE22058_GPL6793	100		1.1359		5.53 0.8417			3.22	[2.80; 3.65	
GSE22405_GPL10553	24		0.1119		2.66 0.0534		1 =		[0.96; 2.28	
GSE25097_GPL10687	268		0.2021		2.14 0.0318				[1.62; 2.01	
GSE33294_GPL10999	3		0.8352		0.35 0.2366				[-0.24; 7.2	
GSE46408_GPL4133	6		0.9293		5.38 0.6323			3.93	[1.70; 6.15	
GSE46444_GPL13369	88		1.1866		7.43 1.8005		이 막 흔 이 이 이 이 이 이 이 이 이 이 이 이 이 이 이 이 이		[-0.82; -0.1	
GSE50579_GPL14550	67		0.3742		1.96 0.3729		1 =		[1.51; 3.03	
GSE54238_GPL16955	26		1.0602		6.27 0.4120			2.06	[1.40; 2.71	
GSE55048_GPL9115	4		0.8107		0.17 0.0969			3.37	[0.67; 6.07	
GSE56545_GPL15433	21		0.2282		2.56 0.1783			2.39	[1.58; 3.20	
GSE57555_GPL16699	5	-0.17 (-0.15 0.0356		-	-0.69	[-1.99; 0.6	-
GSE59259_GPL18451	8		1.2570	8	7.36 0.6048			2.44	[1.06; 3.82	-
GSE60502_GPL96	18		1.1789		4.48 0.8967			3.47	[2.40; 4.54] 2.1%
GSE63898_GPL13667	228 3	-0.22	0.9739		4.33 0.2214			1.70	[1.46; 1.93	3.4%
GSE67764_GPL17077 GSE76311_GPL17586	62		1.3234 0.1527	59	2.38 0.0318			2.36	[0.35; 4.37	·] 1.1%
	371		1.1018		0.51 0.6734		1.8	2.18	[1.73; 2.64	-
TCGA_GTEx_liver	5/1	2.59	1.1018	2/0	0.51 0.0/34			2.10	[2.00; 2.40	-
Random effects mode	el 3857	7		3132			•		[1.63; 2.1	
Heterogeneity: $I^2 = 93\%$,	2 _ 0	1711 0	- 0.01				i i			-
Heterogeneity: $I^- = 93\%$,	1 = 0.4	4/11, P <	0.01			-10 -5	0 5	10		

С					ASPM		
Study	Total	Experimental Mean SD		Control Mean SD	Standardised Mean difference	SMD	95%CI Weight
E_MTAB_4171 E_MTAB_8887 GPL10558	15 23 523	11.20 1.1813 3.71 0.7203 6.39 0.5341	15 17 403	7.41 0.9139 3.22 0.8479 5.46 0.2855		3.50 0.62 2.08	[2.31; 4.68] 2.1% [-0.02; 1.26] 3.0% [1.92; 2.24] 3.6%
GPL11154	163	1.60 1.1896	403 140	0.53 0.6435		1.09	[0.85; 1.33] 3.5%
GPL14951 GPL16043	93 25	7.48 0.8437 1.54 2.1034	18 25	6.67 0.3989 1.30 2.4125	+	1.02 0.11	[0.49; 1.54] 3.2% [-0.45; 0.66] 3.1%
GPL16791 GPL21047	79	5.41 1.7966	78	3.29 1.2488	T <u>i</u>	1.36	[1.02; 1.71] 3.4%
GPL5175	10 48	3.14 0.3182 2.82 0.2001	10 48	2.59 0.1292 2.25 0.0844		2.18 3.67	[1.03; 3.34] 2.1% [3.01; 4.33] 2.9%
GPL570 GPL571	844 96	3.86 0.5731 2.59 0.3866	528 131	2.81 0.3901 2.29 0.0919		2.05 1.13	[1.92; 2.18] 3.6% [0.84; 1.41] 3.5%
GPL6244	66	3.38 0.3254	75	2.91 0.1396	+	1.92	[1.52; 2.32] 3.3%
GPL6480 GPL6947	83 104	3.11 0.2840 3.14 0.2034	82 97	2.75 0.2221 2.89 0.1068	+	1.41 1.55	[1.07; 1.76] 3.4% [1.24; 1.87] 3.4%
GPL9052 GSE115018_GPL20115	60 12	3.00 1.1682 -0.67 0.9087		-0.51 0.8876 -2.30 0.3025	-	3.37 2.32	[2.80; 3.93] 3.1% [1.25; 3.40] 2.2%
GSE124535_GPL20795	35	1.85 0.9419	35	0.33 0.3106		2.15	[1.56; 2.75] 3.0%
GSE125469_GPL20301 GSE128274_GPL18573	3 4	6.13 1.6736 5.77 1.0369	3 4	1.82 0.2768 2.81 0.7829		2.88 2.80	[-0.33; 6.08] 0.6% [0.43; 5.17] 0.9%
GSE14520_GPL3921 GSE166163_GPL23126	225 3	2.94 0.2756 5.30 1.8712	220 3	2.24 0.1406 5.15 2.0559	-	3.17 0.06	[2.89; 3.45] 3.5% [-1.54; 1.66] 1.5%
GSE20140_GPL18461	35	8.16 0.7399	34	7.10 0.3052		1.85	[1.28; 2.42] 3.1%
GSE22058_GPL6793 GSE22405_GPL10553	100 24	8.36 1.1661 2.72 0.2650	97 24	4.95 0.7607 2.39 0.0571		3.43 1.69	[2.99; 3.88] 3.3% [1.02; 2.35] 2.9%
GSE25097_GPL10687 GSE33294 GPL10999	268 3	2.32 0.1944 4.11 0.5499	289 3	2.05 0.0274 0.43 0.2595		1.98 - 6.85	[1.78; 2.19] 3.5% [0.04; 13.65] 0.1%
GSE46408_GPL4133	6	10.52 0.8575	6	5.43 1.4916		3.86	[1.66; 6.06] 1.0%
GSE46444_GPL13369 GSE50579_GPL14550	88 67	7.22 1.1769 3.21 0.2931	48 10	7.01 1.2000 2.52 0.2038		2.39	[-0.17; 0.53] 3.4% [1.62; 3.16] 2.7%
GSE55048_GPL9115 GSE56545_GPL15433	4 21	1.97 0.6096 3.25 0.2292	4 21	0.15 0.0672 2.48 0.2708		3.66 3.03	[0.79; 6.53] 0.7% [2.12; 3.94] 2.5%
GSE57555_GPL16699	5 8	-0.13 0.0395 8.92 1.6839		-0.15 0.0342 6.35 0.7639	<u>+</u>		[-0.81; 1.72] 1.9% [0.63; 3.08] 2.0%
GSE59259_GPL18451 GSE60502_GPL96	18	9.43 0.8899	18	5.72 1.5843	1	2.82	[1.87; 3.77] 2.4%
GSE63898_GPL13667 GSE67764_GPL17077	228 3	6.52 1.1866 0.11 1.4111	168 6 ·	4.53 0.3621 -1.67 0.3701		2.14 1.94	[1.89; 2.39] 3.5% [0.11; 3.76] 1.3%
GSE76311_GPL17586 TCGA_GTEx_liver	62 371	2.81 0.2582 2.21 0.9933	59 276	2.17 0.0704 0.43 0.4502	+	3.31 2.20	[2.76; 3.87] 3.1% [2.01; 2.40] 3.6%
		2.21 0.9995		0.15 0.1502			
Random effects mode Heterogeneity: $I^2 = 93\%$		1702 R < 0.01	3080			2.00	[1.74; 2.25] 100.0%
D	, 1 = 0.4	735, F < 0.01			-10 -5 0 5 10		
				KI	F11		
-	Total	Experimental		Control	Standardised	SMD	95%CI Woight
Study		Mean SD	Total	Control Mean SD	Standardised Mean difference	SMD	95%CI Weight
E_MTAB_4171 E_MTAB_8887	15 23	Mean SD 8.48 0.8570 3.68 0.7774	Total 15 17	Control	Standardised	1.64	[0.80; 2.49] 2.5% [-0.30; 0.97] 2.8%
Study E_MTAB_4171	15 23 523	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469	Total 15 17 403	Control Mean SD 7.10 0.7780 3.42 0.7716 4.91 0.0896	Standardised Mean difference	1.64 0.33 1.30	[0.80; 2.49] 2.5% [-0.30; 0.97] 2.8% [1.16; 1.44] 3.4%
E_MTAB_4171 E_MTAB_8887 GPL110558 GPL11154 GPL14951	15 23 523 163 93	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953	Total 15 17 403 140 18	Control Mean SD 7.10 0.7780 3.42 0.7716 4.91 0.0896 0.56 0.3578 7.04 0.8820	Standardised Mean difference	1.64 0.33 1.30 0.94 0.28	[0.80; 2.49] 2.5% [-0.30; 0.97] 2.8% [1.16; 1.44] 3.4% [0.71; 1.18] 3.3% [-0.22; 0.79] 3.0%
E_MTAB_4171 E_MTAB_8887 GPL10558 GPL1154 GPL14951 GPL16043 GPL21047	15 23 523 163 93 25 10	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953 1.42 0.9520 2.60 0.3531	Total 15 17 403 140 18 25 10	Control Mean SD 7.10 0.7780 3.42 0.7716 4.91 0.0896 0.56 0.3578 7.04 0.8820 1.37 1.1153 2.12 0.1505	Standardised Mean difference	1.64 0.33 1.30 0.94 0.28 0.05 1.69	[0.80; 2.49] 2.5% [-0.30; 0.97] 2.8% [1.16; 1.44] 3.4% [0.71; 1.18] 3.3% [-0.22; 0.79] 3.0% [-0.51; 0.60] 2.9% [0.63; 2.74] 2.1%
E_MTAB_4171 E_MTAB_8887 GPL10558 GPL11154 GPL14951 GPL16043	15 23 523 163 93 25 10 48	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953 1.42 0.9520 2.60 0.3531 2.56 0.2012	Total 15 17 403 140 18 25 10 48	Control Mean SD 7.10 0.7780 3.42 0.7716 4.91 0.0896 0.56 0.3578 7.04 0.8820 1.37 1.1153 2.12 0.1505 2.09 0.0995	Standardised Mean difference	1.64 0.33 1.30 0.94 0.28 0.05 1.69 2.95	[0.80; 2.49] 2.5% [-0.30; 0.97] 2.8% [1.16; 1.44] 3.4% [0.71; 1.18] 3.3% [-0.22; 0.79] 3.0% [-0.51; 0.60] 2.9% [0.63; 2.74] 2.1% [2.36; 3.53] 2.9%
E_MTAB_4171 E_MTAB_8887 GPL10558 GPL11154 GPL14951 GPL16043 GPL21047 GPL5175 GPL570 GPL571	15 23 523 163 93 25 10 48 844 96	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953 1.42 0.9520 2.60 0.3531 2.56 0.2012 3.46 0.6503 2.37 0.1487	Total 15 17 403 140 18 25 10 48 528 131	Control Mean SD 7.10 0.7780 3.42 0.7716 4.91 0.0896 0.56 0.3578 7.04 0.8820 1.37 1.1153 2.12 0.1505 2.09 0.0995 2.61 0.3617 2.29 0.0414	Standardised Mean difference	1.64 0.33 1.30 0.94 0.28 0.05 1.69 2.95 1.52 0.82	$\begin{bmatrix} 0.80; 2.49 \\ 2.5\% \\ [-0.30; 0.97] 2.8\% \\ [1.16; 1.44] 3.4\% \\ [0.71; 1.18] 3.3\% \\ [-0.22; 0.79] 3.0\% \\ [-0.51; 0.60] 2.9\% \\ [0.63; 2.74] 2.1\% \\ [2.36; 3.53] 2.9\% \\ [1.39; 1.64] 3.4\% \\ [0.55; 1.09] 3.3\% \\ \end{bmatrix}$
E_MTAB_4171 E_MTAB_8887 GPL110558 GPL11154 GPL14951 GPL16043 GPL21047 GPL5175 GPL570 GPL571 GPL5244 GPL6480	15 23 523 163 93 25 10 48 844 96 66 83	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953 1.42 0.9520 2.60 0.3531 2.56 0.2012 3.46 0.6503 2.37 0.1487 3.09 0.2558 2.69 0.2079	Total 15 17 403 140 18 25 10 48 528 131 75 82	Control Mean SD 7.10 0.7780 3.42 0.7716 4.91 0.0896 0.56 0.3578 7.04 0.8820 1.37 1.1153 2.12 0.1505 2.09 0.0995 2.61 0.3617	Standardised Mean difference	1.64 0.33 1.30 0.94 0.28 0.05 1.69 2.95 1.52 0.82 1.43 1.42	[0.80; 2.49] 2.5% [-0.30; 0.97] 2.8% [1.16; 1.44] 3.4% [0.71; 1.18] 3.3% [-0.22; 0.79] 3.0% [-0.51; 0.60] 2.9% [0.63; 2.74] 2.1% [2.36; 3.53] 2.9% [1.39; 1.64] 3.4% [0.55; 1.09] 3.3% [1.06; 1.81] 3.2% [1.07; 1.76] 3.2%
E_MTAB_4171 E_MTAB_8887 GPL10558 GPL11154 GPL14951 GPL16043 GPL21047 GPL5175 GPL570 GPL571 GPL6244	15 23 523 163 93 25 10 48 844 96 66 83 104	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953 1.42 0.9520 2.60 0.3531 2.56 0.2012 3.46 0.6503 2.37 0.1487 3.09 0.2558 2.69 0.2079 2.64 0.1995	Total 15 17 403 140 18 25 10 48 528 131 75 82 97	Control Mean SD 3.42 0.7716 4.91 0.896 0.56 0.3578 7.04 0.8820 1.37 1.1153 2.12 0.1505 2.09 0.0995 2.61 0.3617 2.29 0.0414 2.81 0.1147 2.43 0.1500 2.70 0.1835	Standardised Mean difference	1.64 0.33 1.30 0.94 0.28 0.05 1.69 2.95 1.52 0.82 1.43 1.42 -0.29	$\begin{bmatrix} 0.80; 2.49 \\ 2.5\% \\ [-0.30; 0.97 \\ 2.8\% \\ [1.16; 1.44] 3.4\% \\ [0.71; 1.18] 3.3\% \\ [-0.22; 0.79] 3.0\% \\ [-0.51; 0.60] 2.9\% \\ [0.63; 2.74] 2.1\% \\ [2.36; 3.53] 2.9\% \\ [1.39; 1.64] 3.4\% \\ [0.55; 1.09] 3.3\% \\ [1.06; 1.81] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [-0.57; -0.01] 3.3\% \\ \end{bmatrix}$
Study E_MTAB_4171 E_MTAB_8887 GPL10558 GPL11154 GPL14951 GPL16043 GPL21047 GPL5175 GPL570 GPL570 GPL571 GPL6244 GPL6480 GPL6947 GPL952 GSE10143_GPL5474	15 23 523 163 93 25 10 48 844 96 66 83 104 60 80	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953 1.42 0.9520 2.60 0.3531 2.56 0.2012 3.46 0.6503 2.37 0.1487 3.09 0.2558 2.69 0.2079 1.59 0.8383 10.99 0.5571	Total 15 17 403 140 18 25 10 48 528 131 75 82 97 60 307	Control Mean SD 7.10 0.7780 3.42 0.7716 4.91 0.0896 0.56 0.3578 7.04 0.8820 1.37 1.153 2.12 0.1505 2.09 0.0995 2.61 0.3617 2.29 0.0414 2.81 0.1147 2.43 0.1500 2.70 0.1835 -0.86 0.6832 9.19 0.8525	Standardised Mean difference	1.64 0.33 1.30 0.94 0.28 0.05 1.69 2.95 1.52 0.82 1.43 1.42 -0.29 3.19 2.25	$\begin{bmatrix} 0.80; 2.49 \\ -0.30; 0.97 \\ 2.8\% \\ \hline \\ 1.16; 1.44 \\ 3.4\% \\ \hline \\ 0.71; 1.18 \\ 3.3\% \\ \hline \\ -0.22; 0.79 \\ 3.0\% \\ \hline \\ -0.51; 0.60 \\ 2.9\% \\ \hline \\ 1.39; 1.64 \\ 3.4\% \\ \hline \\ 1.25; 1.09 \\ 3.3\% \\ \hline \\ 1.06; 1.81 \\ 3.2\% \\ \hline \\ 1.07; 1.76 \\ 3.2\% \\ \hline \\ 1.05; 3.74 \\ 3.0\% \\ \hline \\ 1.96; 2.55 \\ 3.3\% \\ \hline \end{bmatrix}$
Study E_MTAB_4171 E_MTAB_8887 GPL10558 GPL1154 GPL14951 GPL16043 GPL21047 GPL570 GPL570 GPL571 GPL6244 GPL6480 GPL6947 GPL9052 GSE10143_GPL5474 GSE114783_GPL15491 GSE115018_GPL20115	15 23 523 163 25 10 48 844 96 66 83 104 60 80 80 80 10	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953 1.42 0.9520 2.60 0.3531 2.56 0.2012 3.46 0.6503 2.37 0.1487 3.09 0.2558 2.69 0.2079 2.64 0.1995 1.59 0.8383 10.99 0.5571 7.00 0.9555 0.03 0.8619	Total 15 17 403 140 18 25 10 48 528 131 75 82 97 60 307 26 12	Control Mean SD 7.10 0.7780 3.42 0.7716 4.91 0.0896 0.56 0.3578 7.04 0.8200 1.37 1.1153 2.12 0.1505 2.09 0.0995 2.61 0.3617 2.29 0.0414 2.81 0.1147 2.43 0.1500 2.70 0.1835 -0.86 0.6832 9.19 0.8525 7.14 0.9872 -1.25 0.3305	Standardised Mean difference	$\begin{array}{c} 1.64\\ 0.33\\ 1.30\\ 0.94\\ 0.28\\ 0.05\\ 1.69\\ 2.95\\ 1.52\\ 0.82\\ 1.43\\ 1.42\\ -0.29\\ 3.19\\ 2.25\\ -0.14\\ 1.90\end{array}$	$\begin{bmatrix} 0.80; 2.49 \\ 2.5\% \\ [-0.30; 0.97] 2.8\% \\ [1.16; 1.44] 3.4\% \\ [0.71; 1.18] 3.3\% \\ [-0.22; 0.79] 3.0\% \\ [-0.51; 0.60] 2.9\% \\ [0.63; 2.74] 2.1\% \\ [2.36; 3.53] 2.9\% \\ [1.39; 1.64] 3.4\% \\ [0.55; 1.09] 3.3\% \\ [1.06; 1.81] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [-0.57; -0.01] 3.3\% \\ [2.65; 3.74] 3.0\% \\ [1.96; 2.55] 3.3\% \\ [-0.87; 0.59] 2.7\% \\ [0.91; 2.89] 2.2\% \end{bmatrix}$
Study E_MTAB_4171 E_MTAB_8887 GPL10558 GPL11154 GPL14951 GPL2047 GPL5175 GPL570 GPL570 GPL570 GPL571 GPL6244 GPL6480 GPL6947 GPL9052 GSE10143_GPL5474 GSE114783_GPL5474 GSE114783_GPL20115 GSE124535_GPL20795	15 23 523 163 93 25 10 48 844 96 66 83 104 60 80 10	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953 1.42 0.9520 2.60 0.3531 2.56 0.2012 3.46 0.6503 2.37 0.1487 3.09 0.2558 2.69 0.2079 2.64 0.1995 1.59 0.8383 10.99 0.5571 7.00 0.9951 7.03 0.8619 1.23 0.7787	Total 15 17 403 140 18 25 10 48 528 131 75 82 97 60 307 26	Control Mean SD 7.10 0.7780 3.42 0.7716 4.91 0.0896 0.56 0.3578 7.04 0.8820 1.37 1.1153 2.12 0.1505 2.09 0.0995 2.61 0.3617 2.29 0.0414 2.81 0.1147 2.43 0.1500 2.70 0.1835 -0.86 0.6832 9.19 0.8525 7.14 0.9872 -1.25 0.3305 0.34 0.2243	Standardised Mean difference	$\begin{array}{c} 1.64\\ 0.33\\ 1.30\\ 0.94\\ 0.28\\ 0.05\\ 1.69\\ 2.95\\ 1.52\\ 0.82\\ 1.43\\ 1.42\\ -0.29\\ 3.19\\ 2.25\\ -0.14\\ 1.90\\ 1.53\end{array}$	$\begin{bmatrix} 0.80; 2.49 \\ -0.30; 0.97 \\ 2.8\% \\ \hline \\ \begin{bmatrix} 1.16; 1.44 \\ 3.4\% \\ 0.71; 1.18 \\ 3.3\% \\ \hline \\ \begin{bmatrix} -0.22; 0.79 \\ 3.0\% \\ \hline \\ -0.51; 0.60 \\ 2.9\% \\ \hline \\ \begin{bmatrix} 0.63; 2.74 \\ 2.1\% \\ 1.39; 1.64 \\ 3.4\% \\ \hline \\ \begin{bmatrix} 0.55; 1.09 \\ 3.3\% \\ \hline \\ 1.06; 1.81 \\ 3.2\% \\ \hline \\ 1.07; 1.76 \\ 3.2\% \\ \hline \\ \begin{bmatrix} -0.57; -0.01 \\ 3.3\% \\ \hline \\ \begin{bmatrix} 1.96; 2.55 \\ 3.74 \\ 3.0\% \\ \hline \\ \end{bmatrix} $
Study E_MTAB_4171 E_MTAB_8887 GPL10558 GPL11154 GPL14951 GPL16043 GPL21047 GPL575 GPL570 GPL571 GPL6244 GPL6480 GPL6947 GPL9052 GSE10143_GPL5474 GSE114783_GPL5474 GSE114783_GPL5474 GSE114783_GPL5474 GSE114783_GPL20115 GSE125469_GPL203011 GSE128454_GPL18573	15 233 163 93 25 100 48 844 96 66 68 83 104 60 80 80 10 12 35 3 4	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953 1.42 0.9520 2.60 0.3531 2.56 0.2012 3.46 0.6503 2.37 0.1487 3.09 0.2558 2.69 0.2079 2.64 0.1995 1.59 0.8383 10.99 0.5571 7.00 0.9955 0.03 0.8619 1.23 0.7787 4.61 1.1976 4.81 0.8515	Total 15 17 403 140 18 25 10 48 528 131 75 82 97 60 307 26 12 35 3 4	Control Mean SD 7.10 0.7780 3.42 0.7716 4.91 0.0896 0.56 0.3578 7.04 0.8820 1.37 1.1153 2.12 0.1505 2.09 0.0995 2.61 0.3617 2.29 0.0414 2.81 0.1147 2.43 0.1500 2.70 0.1835 -0.86 0.6832 9.19 0.8525 7.14 0.9872 -1.25 0.3305 0.34 0.2243 1.81 0.2803 2.73 0.4154	Standardised Mean difference	$\begin{array}{c} 1.64\\ 0.33\\ 1.30\\ 0.94\\ 0.28\\ 0.05\\ 1.69\\ 2.95\\ 1.52\\ 0.82\\ 1.42\\ -0.29\\ 3.19\\ 2.25\\ -0.14\\ 1.90\\ 1.53\\ 2.65\\ 2.69\end{array}$	$ \begin{bmatrix} 0.80; 2.49 \\ 2.5\% \\ [-0.30; 0.97] 2.8\% \\ [1.16; 1.44] 3.4\% \\ [0.71; 1.18] 3.3\% \\ [-0.22; 0.79] 3.0\% \\ [-0.51; 0.60] 2.9\% \\ [0.63; 2.74] 2.1\% \\ [2.36; 3.53] 2.9\% \\ [1.39; 1.64] 3.4\% \\ [0.55; 1.09] 3.3\% \\ [1.06; 1.81] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [-0.57; -0.01] 3.3\% \\ [2.65; 3.74] 3.0\% \\ [1.95; 2.55] 3.3\% \\ [-0.87; 0.59] 2.7\% \\ [0.91; 2.89] 2.2\% \\ [1.00; 2.07] 3.0\% \\ [-0.37; 5.67] 0.6\% \\ [0.38; 5.00] 0.9\% \\ \end{bmatrix} $
Study E_MTAB_4171 E_MTAB_8887 GPL10558 GPL11154 GPL14951 GPL20047 GPL570 GPL570 GPL570 GPL570 GPL571 GPL6244 GPL6480 GPL6947 GPL9052 GSE10143_GPL5474 GSE114783_GPL15491 GSE115018_GPL20115 GSE124535_GPL20795 GSE128274_GPL18573 GSE12450_GPL3921 GSE166163_GPL23126	15 233 163 93 255 10 48 844 96 66 83 104 66 80 10 112 35 3 4 225 3	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953 1.42 0.9520 2.60 0.3531 2.56 0.2012 3.46 0.6503 2.37 0.1487 3.09 0.2558 2.69 0.2079 2.64 0.1995 1.59 0.8383 10.99 0.5571 7.00 0.9955 0.03 0.6619 1.23 0.7787 4.69 1.1976 4.81 0.8515 2.38 0.2172 4.00 1.5910	Total 15 17 403 140 18 25 10 48 528 131 75 82 97 60 307 26 12 35 3 4 220 3	Control Mean SD 3.42 0.7716 4.91 0.0896 0.56 0.3578 7.04 0.8820 1.37 1.1153 2.12 0.1505 2.09 0.0995 2.61 0.3617 2.29 0.0414 2.81 0.1147 2.43 0.1500 2.70 0.1835 -0.86 0.6832 9.19 0.8525 7.14 0.9872 -1.25 0.3305 0.34 0.2243 1.81 0.2803 2.73 0.4154 1.81 0.2803 2.73 0.4154 1.81 0.755 3.47 2.4617	Standardised Mean difference	$\begin{array}{c} 1.64\\ 0.33\\ 1.30\\ 0.94\\ 0.28\\ 0.05\\ 1.69\\ 2.95\\ 1.52\\ 0.82\\ 1.43\\ 1.42\\ -0.29\\ 3.19\\ 2.25\\ -0.14\\ 1.90\\ 1.53\\ 2.65\\ 2.69\\ 1.66\\ 0.20\\ \end{array}$	$ \begin{bmatrix} 0.80; 2.49 \\ -0.30; 0.97 \\ 2.8\% \\ \hline \\ $
Study E_MTAB_4171 E_MTAB_8887 GPL10558 GPL11154 GPL14951 GPL16043 GPL21047 GPL570 GPL570 GPL571 GPL6244 GPL6480 GPL6947 GPL9052 GSE10143_GPL5474 GSE114783_GPL15491 GSE125469_GPL20301 GSE128274_GPL18573 GSE14520_GPL3921	15 23 163 93 25 10 48 844 96 66 83 104 60 80 10 12 35 3 4 225	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953 1.42 0.9520 2.60 0.3531 2.56 0.2012 3.46 0.6503 2.37 0.1487 3.09 0.2558 2.69 0.2079 2.64 0.1995 1.59 0.8383 10.99 0.5571 7.00 0.9955 0.03 0.8619 1.23 0.7787 4.81 0.8515 2.38 0.2172	Total 15 17 403 140 18 25 10 48 528 131 75 82 97 60 307 26 12 3 4 220	Control Mean SD 7.10 0.7780 3.42 0.7716 4.91 0.0896 0.56 0.3578 7.04 0.8820 1.37 1.1153 2.12 0.1505 2.09 0.0995 2.61 0.3617 2.29 0.0414 2.81 0.1147 2.43 0.1500 2.70 0.1835 -0.86 0.6832 9.19 0.8525 7.14 0.9872 -1.25 0.3305 0.34 0.2243 1.81 0.2803 2.73 0.4154 2.71 0.0755	Standardised Mean difference	$\begin{array}{c} 1.64\\ 0.33\\ 1.30\\ 0.94\\ 0.28\\ 0.05\\ 1.69\\ 2.95\\ 1.52\\ 0.82\\ 1.43\\ 1.42\\ -0.29\\ 3.19\\ 2.25\\ -0.14\\ 1.90\\ 1.53\\ 2.65\\ 2.69\\ 1.66\\ 0.20\\ \end{array}$	$ \begin{bmatrix} 0.80; 2.49 \\ 2.5\% \\ [-0.30; 0.97] 2.8\% \\ [1.16; 1.44] 3.4\% \\ [0.71; 1.18] 3.3\% \\ [-0.22; 0.79] 3.0\% \\ [-0.51; 0.60] 2.9\% \\ [0.63; 2.74] 2.1\% \\ [2.36; 3.53] 2.9\% \\ [1.39; 1.64] 3.4\% \\ [0.55; 1.09] 3.3\% \\ [1.06; 1.81] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [-0.57; -0.01] 3.3\% \\ [2.65; 3.74] 3.0\% \\ [2.65; 3.74] 3.0\% \\ [2.65; 3.74] 3.0\% \\ [1.96; 2.55] 3.3\% \\ [-0.87; 0.59] 2.7\% \\ [0.91; 2.89] 2.2\% \\ [1.00; 2.07] 3.0\% \\ [-0.37; 5.67] 0.6\% \\ [0.38; 5.00] 0.9\% \\ [1.45; 1.88] 3.4\% \\ [-1.41; 1.82] 1.4\% \\ [1.10; 2.20] 3.0\% \\ \end{bmatrix} $
Study E_MTAB_4171 E_MTAB_8887 GPL10558 GPL11154 GPL14951 GPL16043 GPL21047 GPL570 GPL570 GPL571 GPL6244 GPL6480 GPL6947 GPL9052 GSE10143_GPL5474 GSE114783_GPL15491 GSE115018_GPL20115 GSE124535_GPL20795 GSE124535_GPL20795 GSE128274_GPL18573 GSE14520_GPL3921 GSE166163_GPL23126 GSE20140_GPL38461 GSE22058_GPL6793 GSE22405_GPL10553	$\begin{array}{c} 15\\ 23\\ 523\\ 163\\ 93\\ 25\\ 10\\ 48\\ 844\\ 96\\ 66\\ 83\\ 104\\ 60\\ 80\\ 10\\ 12\\ 35\\ 3\\ 4\\ 225\\ 3\\ 35\\ 100\\ 24\end{array}$	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953 1.42 0.9520 2.60 0.3531 2.56 0.2012 3.46 0.6503 2.37 0.1487 3.09 0.2558 2.69 0.2079 2.64 0.1995 1.59 0.8383 10.99 0.5571 7.00 0.9955 0.03 0.8619 1.23 0.7787 4.69 1.1976 4.81 0.8515 2.38 0.2172 4.00 1.5910 7.70 0.3119 8.70 0.9390 2.48 0.0875	Total 15 17 403 140 18 25 10 48 528 131 75 82 97 60 307 26 3 4 220 3 4 220 3 4 220 3 4 200 3 97 220 3 4 220 3 4 200 3 97 24	Control Mean SD 7.10 0.7780 3.42 0.7716 4.91 0.0896 0.56 0.3578 7.04 0.8820 1.37 1.1153 2.12 0.1505 2.09 0.0995 2.61 0.3617 2.29 0.0414 2.81 0.1147 2.43 0.1500 2.70 0.1835 -0.86 0.6832 9.19 0.8525 7.14 0.9872 -1.25 0.3305 0.34 0.2243 1.81 0.2803 2.73 0.4154 2.11 0.0755 3.47 2.4617 6.90 0.1040 6.52 0.6235 2.38 0.0272	Standardised Mean difference	$\begin{array}{c} 1.64\\ 0.33\\ 1.30\\ 0.94\\ 0.28\\ 0.05\\ 1.69\\ 2.95\\ 1.52\\ 0.82\\ 1.43\\ 1.42\\ -0.29\\ 3.19\\ 2.25\\ -0.14\\ 1.90\\ 1.53\\ 2.65\\ 2.65\\ 2.65\\ 2.65\\ 2.65\\ 2.65\\ 1.66\\ 0.20\\ 1.65\\ 2.71\\ 1.50\end{array}$	$ \begin{bmatrix} 0.80; 2.49 \\ -0.30; 0.97 \\ 2.8\% \\ \hline \\ $
Study E_MTAB_4171 E_MTAB_8887 GPL10558 GPL11154 GPL14951 GPL16043 GPL21047 GPL575 GPL570 GPL571 GPL6244 GPL6480 GPL6947 GPL9052 GSE10143_GPL5474 GSE114783_GPL15491 GSE124535_GPL20151 GSE125469_GPL20301 GSE125469_GPL20301 GSE125469_GPL20301 GSE125469_GPL20301 GSE125469_GPL20301 GSE125469_GPL20301 GSE125469_GPL20301 GSE125469_GPL20301 GSE125469_GPL20301 GSE125469_GPL20301 GSE126163_GPL31266 GSE20140_GPL18461 GSE22058_GPL6793 GSE22405_GPL10657 GSE32294_GPL10697	15 233 523 163 93 25 10 48 844 966 83 104 60 80 10 12 35 3 4 225 3 35 100 24 268 3	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953 1.42 0.9520 2.60 0.3531 2.56 0.2012 3.46 0.6503 2.37 0.1487 3.09 0.2558 2.69 0.2079 2.64 0.1995 0.30 0.8615 1.59 0.8383 10.99 0.5571 7.00 0.9955 0.30 0.8615 2.38 0.2172 4.69 1.1976 4.81 0.8515 2.38 0.2172 4.00 1.5910 7.29 0.3119 8.70 0.93900 2.44 0.1550 2.44 0.1550 2.44 0.1550 2.44 0.1550	Total 15 17 403 140 25 10 48 131 75 82 97 60 307 26 12 34 97 24 334 97 24 289 3 34 97 24 289 3	Control Mean SD 7.10 0.7780 3.42 0.7716 4.91 0.0896 0.56 0.3578 7.04 0.8820 1.37 1.1153 2.12 0.1505 2.09 0.0995 2.61 0.3617 2.29 0.0414 2.81 0.1147 2.43 0.1500 2.70 0.1835 -0.86 0.6832 9.19 0.8525 7.14 0.9872 9.19 0.8525 7.14 0.9872 9.19 0.8525 7.14 0.9872 9.19 0.8525 7.14 0.9872 9.19 0.8525 7.14 0.9872 9.19 0.8525 7.14 0.9872 3.47 2.4617 6.90 0.1040 6.52 0.6235 2.38 0.0272 2.24 0.0438 0.47 0.2874	Standardised Mean difference	1.64 0.33 1.30 0.94 0.28 0.05 1.69 2.95 1.52 0.82 1.43 1.42 -0.29 3.19 2.25 -0.14 1.90 1.53 2.65 2.69 1.66 0.20 1.65 2.71 1.56 0.20 1.76 - 6.04	$ \begin{bmatrix} 0.80; 2.49 \\ 2.5\% \\ [-0.30; 0.97] 2.8\% \\ [1.16; 1.44] 3.4\% \\ [0.71; 1.18] 3.3\% \\ [-0.22; 0.79] 3.0\% \\ [-0.51; 0.60] 2.9\% \\ [0.63; 2.74] 2.1\% \\ [2.36; 3.53] 2.9\% \\ [1.39; 1.64] 3.4\% \\ [0.55; 1.09] 3.3\% \\ [1.06; 1.81] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [2.65; 3.74] 3.0\% \\ [2.65; 3.74] 3.0\% \\ [2.65; 3.74] 3.0\% \\ [1.96; 2.55] 3.3\% \\ [-0.87; 0.59] 2.7\% \\ [0.91; 2.89] 2.2\% \\ [1.00; 2.07] 3.0\% \\ [0.38; 5.00] 0.9\% \\ [1.45; 1.88] 3.4\% \\ [-1.41; 1.82] 1.4\% \\ [1.10; 2.20] 3.0\% \\ [2.32; 3.10] 3.2\% \\ [0.36; 2.15] 2.8\% \\ [1.55; 1.95] 3.4\% \\ [-0.71; 12.09] 0.2\% $
Study E_MTAB_4171 E_MTAB_8887 GPL10558 GPL11154 GPL14951 GPL16043 GPL21047 GPL570 GPL570 GPL571 GPL6244 GPL6440 GPL6947 GPL9052 GSE10143_GPL5474 GSE114783_GPL15491 GSE115018_GPL20115 GSE124535_GPL20795 GSE124535_GPL20795 GSE124529_GPL20301 GSE12549_GPL20311 GSE12549_GPL20311 GSE12549_GPL20312 GSE16163_GPL23126 GSE20140_GPL38416 GSE22058_GPL6793 GSE22405_GPL10553 GSE22405_GPL10553 GSE23294_GPL10999 GSE46444_GPL13369	$\begin{array}{c} 15\\ 23\\ 523\\ 163\\ 93\\ 25\\ 10\\ 48\\ 844\\ 96\\ 66\\ 83\\ 104\\ 66\\ 80\\ 10\\ 12\\ 35\\ 3\\ 3\\ 5\\ 100\\ 24\\ 225\\ 3\\ 3\\ 35\\ 100\\ 24\\ 268\\ 3\\ 6\\ 88\end{array}$	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953 1.42 0.9520 2.60 0.3531 2.56 0.2012 3.46 0.6503 2.37 0.1487 3.09 0.2558 2.69 0.2079 2.64 0.1995 0.03 0.8619 1.23 0.7787 4.69 1.1976 4.81 0.8515 2.38 0.2172 4.00 1.5910 7.29 0.3119 8.70 0.3930 2.48 0.0875 2.44 0.1550 8.39 0.3500 8.32 0.3500 8.32 0.3500	Total 15 17 403 140 82 10 48 528 131 75 82 97 60 307 26 3 4200 3 4200 3 4200 3 4200 3 4200 3 4200 3 4200 3 4200 3 4200 3 4200 3 4200 3 4200 3 4200 3 4200 3 4200 3 4200 3 43 6 48	Control Mean SD 3.42 0.7716 4.91 0.0896 0.56 0.3578 7.04 0.8820 1.37 1.1153 2.12 0.1505 2.09 0.0995 2.61 0.3617 2.29 0.0414 2.81 0.1147 2.43 0.1500 2.70 0.1835 -0.86 0.6832 9.19 0.8525 7.14 0.9872 -1.25 0.3305 0.34 0.2243 1.81 0.2803 2.73 0.4154 2.11 0.0755 3.47 2.4617 6.90 0.1040 6.52 0.6235 2.38 0.0272 2.324 0.0438	Standardised Mean difference	$\begin{array}{c} 1.64\\ 0.33\\ 1.30\\ 0.94\\ 0.28\\ 0.05\\ 1.69\\ 2.95\\ 1.52\\ 0.82\\ 1.43\\ 1.42\\ -0.29\\ 3.19\\ 2.25\\ -0.14\\ 1.90\\ 1.53\\ 2.65\\ 2.69\\ 1.53\\ 2.69\\ 1.65\\ 2.71\\ 1.50\\ 1.76\\ -6.04\\ 3.07\\ -0.30\\ \end{array}$	$ \begin{bmatrix} 0.80; 2.49 \\ 2.5\% \\ [-0.30; 0.97] 2.8\% \\ [1.16; 1.44] 3.4\% \\ [0.71; 1.18] 3.3\% \\ [-0.22; 0.79] 3.0\% \\ [-0.51; 0.60] 2.9\% \\ [0.63; 2.74] 2.1\% \\ [2.36; 3.53] 2.9\% \\ [1.39; 1.64] 3.4\% \\ [0.55; 1.09] 3.3\% \\ [1.06; 1.81] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [-0.57; -0.01] 3.3\% \\ [1.06; 1.81] 3.2\% \\ [-0.57; -0.01] 3.3\% \\ [1.96; 2.55] 3.3\% \\ [-0.87; 0.59] 2.7\% \\ [0.91; 2.89] 2.2\% \\ [1.00; 2.07] 3.0\% \\ [-0.37; 5.67] 0.6\% \\ [0.38; 5.00] 0.9\% \\ [1.45; 1.88] 3.4\% \\ [-1.41; 1.82] 1.4\% \\ [1.10; 2.20] 3.0\% \\ [2.32; 3.10] 3.2\% \\ [0.86; 2.15] 2.8\% \\ [1.56; 1.95] 3.4\% \\ [-0.65; 0.06] 3.2\% \\ \end{bmatrix} $
Study E_MTAB_4171 E_MTAB_8887 GPL10558 GPL11154 GPL14951 GPL570 GPL570 GPL570 GPL570 GPL572 GPL570 GPL574 GPL6244 GPL6480 GPL6947 GPL9052 GSE10143_GPL5474 GSE114783_GPL5474 GSE114783_GPL5474 GSE124535_GPL20115 GSE124574_GPL185471 GSE124574_GPL185471 GSE12616163_GPL23126 GSE20140_GPL3921 GSE166163_GPL23126 GSE2097_GPL10687 GSE3294_GPL10553 GSE3294_GPL13369 GSE50579_GPL14550	$\begin{array}{c} 15\\ 23\\ 523\\ 163\\ 93\\ 25\\ 10\\ 48\\ 844\\ 96\\ 66\\ 83\\ 104\\ 60\\ 80\\ 10\\ 12\\ 35\\ 3\\ 4\\ 225\\ 3\\ 35\\ 100\\ 24\\ 268\\ 3\\ 6\\ 8\\ 68\\ 67\\ \end{array}$	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953 1.42 0.9520 2.60 0.3531 2.56 0.2012 3.46 0.6503 2.37 0.1487 3.09 0.2558 2.69 0.2079 2.64 0.1995 1.59 0.8383 10.99 0.5571 7.00 0.9955 0.03 0.8619 1.23 0.7787 4.69 1.1976 4.81 0.8515 2.38 0.2172 4.00 1.5910 7.29 0.3119 8.70 0.9305 2.44 0.8575 2.48 0.8675 2.44 0.1550 2.89 0.3500 6.23 0.8834 2.89 0.2870 6.23	Total 15 17 403 140 18 25 10 48 528 131 75 82 97 60 307 26 60 307 26 60 307 26 12 3 3 4 220 3 3 4 220 3 4 20 3 4 20 3 4 20 3 4 20 20 20 20 20 20 20 20 20 20	Control Mean SD 7.10 0.7780 3.42 0.7716 4.91 0.0896 0.56 0.3578 7.04 0.8820 1.37 1.1153 2.12 0.1505 2.09 0.0995 2.61 0.3617 2.29 0.0414 2.81 0.1147 2.43 0.1500 2.70 0.1835 -0.86 0.6832 9.19 0.8525 7.14 0.9872 -1.25 0.3305 0.34 0.2243 1.81 0.2803 2.73 0.4154 2.11 0.0755 3.47 2.4617 6.90 0.1040 6.52 0.6235 2.38 0.0272 2.34 0.0438 0.47 0.2874 5.62 0.7440 6.49 0.8110 2.46 0.3416	Standardised Mean difference	$\begin{array}{c} 1.64\\ 0.33\\ 1.30\\ 0.94\\ 0.28\\ 0.05\\ 1.69\\ 2.95\\ 1.52\\ 0.82\\ 1.43\\ 1.42\\ -0.29\\ 3.19\\ 2.25\\ -0.14\\ 1.90\\ 1.53\\ 2.65\\ 2.69\\ 1.66\\ 0.20\\ 1.65\\ 2.71\\ 1.53\\ 2.65\\ 2.69\\ 1.66\\ 0.20\\ 1.65\\ 2.71\\ 1.76\\ -0.30\\ 1.82\\ \end{array}$	$ \begin{bmatrix} 0.80; 2.49 \\ 2.5\% \\ [-0.30; 0.97] 2.8\% \\ [1.16; 1.44] 3.4\% \\ [0.71; 1.18] 3.3\% \\ [-0.22; 0.79] 3.0\% \\ [-0.51; 0.60] 2.9\% \\ [1.39; 1.64] 3.4\% \\ [2.36; 3.53] 2.9\% \\ [1.39; 1.64] 3.4\% \\ [0.55; 1.09] 3.3\% \\ [1.06; 1.81] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [-0.57; -0.01] 3.3\% \\ [2.55; 3.74] 3.0\% \\ [1.96; 2.55] 3.3\% \\ [-0.87; 0.59] 2.7\% \\ [0.91; 2.89] 2.2\% \\ [1.00; 1.81] 3.2\% \\ [1.00; 1.81] 3.2\% \\ [1.00; 1.81] 3.2\% \\ [-0.37; 5.67] 0.6\% \\ [0.38; 5.00] 0.9\% \\ [1.45; 1.88] 3.4\% \\ [-1.41; 1.82] 1.4\% \\ [1.10; 2.20] 3.0\% \\ [2.55; 3.10] 3.2\% \\ [1.56; 1.95] 3.4\% \\ [-0.01; 12.09] 0.2\% \\ [1.19; 4.94] 1.2\% \\ [-0.65; 0.06] 3.2\% \\ [1.09; 2.55] 2.7\% \\ \end{bmatrix} $
Study E_MTAB_4171 E_MTAB_8887 GPL10558 GPL1154 GPL14951 GPL16043 GPL21047 GPL570 GPL570 GPL571 GPL6244 GPL6480 GPL6947 GPL9052 GSE10143_GPL5474 GSE114783_GPL15491 GSE125469_GPL20301 GSE128274_GPL18573 GSE14520_GPL3921 GSE166163_GPL3921 GSE166163_GPL3921 GSE12056_GPL3921 GSE2097_GPL10687 GSE2394_GPL10999 GSE46408_GPL4133 GSE46444_GPL13969 GSE50579_GPL1550 GSE50579_GPL1550 GSE50579_GPL15433	$\begin{array}{c} 15\\ 233\\ 523\\ 163\\ 93\\ 25\\ 10\\ 48\\ 844\\ 966\\ 83\\ 104\\ 66\\ 83\\ 104\\ 66\\ 80\\ 10\\ 12\\ 35\\ 3\\ 4\\ 225\\ 3\\ 3\\ 5\\ 100\\ 24\\ 268\\ 3\\ 6\\ 88\\ 67\\ 4\\ 21\\ \end{array}$	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953 1.42 0.9520 2.60 0.3531 2.56 0.2012 3.46 0.6503 2.37 0.1487 3.09 0.2558 2.69 0.2079 2.64 0.1995 1.59 0.8383 10.99 0.5571 7.00 0.9955 0.03 0.8619 1.23 0.7787 4.69 1.1976 4.81 0.8515 2.38 0.2172 4.00 1.5910 8.70 0.9390 2.48 0.8752 2.44 0.1590 2.89 0.2171 1.44 0.4793 3.00 0.2135	Total 15 17 403 140 18 25 10 48 25 131 75 82 97 60 307 26 3 3 4 220 3 4 220 3 4 220 3 4 220 3 4 220 3 4 220 3 4 220 3 4 200 3 4 200 3 4 200 3 4 200 200 200 200 200 200 200	Control Mean SD 7.10 0.7780 3.42 0.7716 4.91 0.0896 0.56 0.3578 7.04 0.8820 1.37 1.1153 2.12 0.1505 2.09 0.0995 2.61 0.3617 2.29 0.0414 2.81 0.1147 2.43 0.1500 2.70 0.1835 -0.86 0.6832 9.19 0.8525 7.14 0.9872 -1.25 0.3305 0.34 0.2243 1.81 0.2803 1.81 0.2803 1.81 0.2803 1.81 0.2803 1.81 0.2803 1.81 0.2803 1.81 0.2803 1.81 0.2803 1.81 0.2803 2.73 0.4154 2.11 0.0755 3.47 2.4617 6.90 0.10438 0.47 0.2874 5.62 0.7440 6.49 0.8110 2.46 0.380 0.999 2.48 0.2099	Standardised Mean difference	$\begin{array}{c} 1.64\\ 0.33\\ 1.30\\ 0.94\\ 0.28\\ 0.05\\ 1.69\\ 2.95\\ 1.52\\ 0.82\\ 1.43\\ 1.42\\ -0.29\\ 3.19\\ 2.25\\ -0.14\\ 1.90\\ 1.53\\ 2.65\\ 2.65\\ 2.65\\ 2.65\\ 2.65\\ 2.65\\ 1.66\\ 0.20\\ 1.65\\ 2.71\\ 1.50\\ 1.66\\ 0.20\\ 1.66\\ 0.20\\ 1.66\\ 0.20\\ 1.66\\ 0.20\\ 1.66\\ 0.20\\ 1.66\\ 0.20\\ 1.66\\ 0.20\\ 1.66\\ 0.20\\ 1.66\\ 0.20\\ 1.62\\ 0.20\\ 1.62\\ 0.20\\ 0.2$	$ \begin{bmatrix} 0.80; 2.49 \\ 2.5\% \\ [-0.30; 0.97] 2.8\% \\ [1.16; 1.44] 3.4\% \\ [0.71; 1.18] 3.3\% \\ [-0.22; 0.79] 3.0\% \\ [-0.51; 0.60] 2.9\% \\ [0.63; 2.74] 2.1\% \\ [2.36; 3.53] 2.9\% \\ [1.39; 1.64] 3.4\% \\ [0.55; 1.09] 3.3\% \\ [1.06; 1.81] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [-0.57; -0.01] 3.3\% \\ [1.06; 1.81] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [-0.57; -0.01] 3.3\% \\ [1.96; 2.55] 3.3\% \\ [-0.87; 0.59] 2.7\% \\ [0.91; 2.89] 2.2\% \\ [1.00; 2.07] 3.0\% \\ [-0.37; 5.67] 0.6\% \\ [0.38; 5.00] 0.9\% \\ [1.45; 1.88] 3.4\% \\ [-1.41; 1.82] 1.4\% \\ [1.10; 2.20] 3.0\% \\ [1.56; 1.95] 3.2\% \\ [0.86; 2.15] 2.8\% \\ [1.56; 1.95] 3.4\% \\ [-0.61; 12.09] 0.2\% \\ [1.19; 4.94] 1.2\% \\ [-0.65; 0.06] 3.2\% \\ [0.37; 4.98] 0.9\% \\ [1.60; 3.23] 2.5\% \\ \end{bmatrix} $
Study E_MTAB_4171 E_MTAB_8887 GPL10558 GPL11154 GPL10558 GPL11154 GPL16043 GPL21047 GPL575 GPL570 GPL571 GPL6244 GPL6480 GPL6947 GPL9052 GSE10143_GPL5474 GSE114783_GPL15491 GSE114783_GPL15491 GSE124555_GPL20795 GSE124555_GPL20795 GSE125469_GPL20301 GSE128274_GPL18573 GSE14520_GPL3921 GSE166163_GPL31266 GSE20140_GPL18461 GSE22058_GPL6793 GSE22405_GPL10687 GSE3294_GPL10687 GSE3294_GPL10687 GSE3294_GPL10999 GSE46444_GPL3369 GSE5048_GPL9115	$\begin{array}{c} 15\\ 23\\ 523\\ 163\\ 93\\ 25\\ 10\\ 48\\ 844\\ 96\\ 68\\ 83\\ 104\\ 60\\ 80\\ 10\\ 12\\ 33\\ 4\\ 225\\ 3\\ 3\\ 5\\ 100\\ 24\\ 268\\ 3\\ 6\\ 88\\ 3\\ 6\\ 88\\ 7\\ 4\end{array}$	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953 1.42 0.9520 2.60 0.3531 2.56 0.2012 3.46 0.6503 2.37 0.1487 3.09 0.2558 2.69 0.2079 2.64 0.1995 0.03 0.8619 1.59 0.8383 10.99 0.5571 7.00 0.9955 0.03 0.8619 1.23 0.7787 4.69 1.1976 4.81 0.8515 2.38 0.2172 4.00 1.5910 8.70 0.33119 8.70 0.3310 8.32 0.8750 2.48 0.8550 2.39 0.3540 8.32 0.8750 2.83 0.2171 1.44	Total 15 17 403 140 18 25 10 48 25 131 75 82 97 60 307 26 3 3 4 220 3 4 220 3 4 220 3 4 220 3 4 220 3 4 220 3 4 220 3 4 200 3 4 200 3 4 200 3 4 200 200 200 200 200 200 200	Control Mean SD 7.10 0.7780 3.42 0.7716 4.91 0.0896 0.56 0.3578 7.04 0.8820 7.04 0.8820 2.12 0.1505 2.09 0.0995 2.61 0.3617 2.29 0.0414 2.81 0.1147 2.43 0.1500 2.70 0.1835 -0.86 0.6832 9.19 0.8525 7.14 0.9872 -1.25 0.3305 0.34 0.2243 1.81 0.2803 2.73 0.4154 2.11 0.0755 3.47 2.4617 6.90 0.1040 6.52 0.6235 2.38 0.0272 2.24 0.438 0.47 0.2874 5.62 0.7440 6.49 0.8110 2.46 0.2999 2.4	Standardised Mean difference	$\begin{array}{c} 1.64\\ 0.33\\ 1.30\\ 0.94\\ 0.28\\ 0.05\\ 1.69\\ 2.95\\ 1.52\\ 0.82\\ 1.43\\ 1.42\\ -0.29\\ 3.19\\ 2.25\\ -0.14\\ 1.90\\ 1.53\\ 2.65\\ 2.65\\ 2.65\\ 2.65\\ 2.65\\ 1.66\\ 0.20\\ 1.65\\ 2.71\\ 1.50\\ 1.66\\ 0.20\\ 1.65\\ 2.71\\ 1.50\\ 1.66\\ 0.20\\ 1.65\\ 2.71\\ 1.50\\ 1.75\\ 1.7$	$ \begin{bmatrix} 0.80; 2.49 \\ 2.5\% \\ [-0.30; 0.97] 2.8\% \\ [1.16; 1.44] 3.4\% \\ [0.71; 1.18] 3.3\% \\ [-0.22; 0.79] 3.0\% \\ [-0.51; 0.60] 2.9\% \\ [0.63; 2.74] 2.1\% \\ [2.36; 3.53] 2.9\% \\ [1.39; 1.64] 3.4\% \\ [0.55; 1.09] 3.3\% \\ [1.06; 1.81] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [-0.57; -0.01] 3.3\% \\ [1.06; 1.81] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [-0.57; -0.01] 3.3\% \\ [1.06; 2.55] 3.3\% \\ [-0.87; 0.59] 2.7\% \\ [0.91; 2.89] 2.2\% \\ [1.00; 2.07] 3.0\% \\ [-0.37; 5.67] 0.6\% \\ [0.38; 5.00] 0.9\% \\ [1.45; 1.88] 3.4\% \\ [-1.41; 1.82] 1.4\% \\ [1.10; 2.20] 3.0\% \\ [2.32; 3.10] 3.2\% \\ [0.86; 2.15] 2.8\% \\ [1.56; 1.95] 3.4\% \\ [-0.65; 0.06] 3.2\% \\ [1.09; 2.55] 2.7\% \\ [0.37; 4.98] 0.9\% \\ [1.60; 3.23] 2.5\% \\ [-2.06; 0.56] 1.8\% \\ \end{bmatrix} $
Study E_MTAB_4171 E_MTAB_8887 GPL10558 GPL1154 GPL14951 GPL16043 GPL21047 GPL570 GPL571 GPL570 GPL571 GPL6244 GPL6480 GPL6947 GPL9052 GSE10143_GPL5474 GSE114783_GPL5474 GSE114783_GPL15491 GSE124535_GPL20795 GSE1245469_GPL20301 GSE128274_GPL18573 GSE14520_GPL3921 GSE166163_GPL23126 GSE20140_GPL38461 GSE2097_GPL10687 GSE3294_GPL10593 GSE3294_GPL10999 GSE46408_GPL4133 GSE46444_GPL3369 GSE55048_GPL9115 GSE5555_GPL16499 GSE5555_GPL16493 GSE5755_GPL18451 GSE60502_GPL96	$\begin{array}{c} 15\\ 23\\ 523\\ 163\\ 93\\ 25\\ 10\\ 48\\ 844\\ 96\\ 66\\ 83\\ 104\\ 60\\ 80\\ 10\\ 12\\ 33\\ 4\\ 225\\ 3\\ 35\\ 100\\ 24\\ 268\\ 8\\ 6\\ 8\\ 8\\ 6\\ 7\\ 4\\ 21\\ 5\\ 8\\ 88\\ 6\\ 7\\ 4\\ 21\\ 5\\ 8\\ 88\\ 7\\ 4\\ 21\\ 5\\ 8\\ 88\\ 7\\ 4\\ 21\\ 5\\ 8\\ 88\\ 7\\ 8\\ 88\\ 7\\ 8\\ 88\\ 7\\ 8\\ 88\\ 7\\ 8\\ 88\\ 7\\ 8\\ 88\\ 7\\ 8\\ 88\\ 7\\ 8\\ 88\\ 7\\ 8\\ 8\\ 8\\ 8\\ 7\\ 8\\ 8\\ 8\\ 8\\ 7\\ 8\\ 8\\ 8\\ 8\\ 8\\ 8\\ 7\\ 8\\ 8\\ 8\\ 8\\ 8\\ 8\\ 8\\ 8\\ 8\\ 8\\ 8\\ 8\\ 8\\$	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953 1.42 0.9520 2.60 0.3531 2.56 0.2012 3.46 0.6503 2.37 0.1487 3.09 0.2558 2.69 0.2079 2.64 0.1995 1.59 0.8383 10.99 0.5571 7.00 0.9955 0.03 0.8619 1.23 0.7787 4.69 1.1976 4.81 0.8515 2.38 0.2172 4.00 1.5910 7.29 0.3119 8.70 0.9390 2.48 0.8550 2.89 0.3500 8.32 0.8750 2.89 0.3500 8.32 0.8750 2.44 0.4793 3.00	Total 15 17 403 140 18 25 10 48 25 131 75 82 97 60 307 26 12 35 4 220 3 34 220 3 4 220 3 4 220 3 4 220 3 4 220 3 4 220 3 4 220 3 4 220 3 4 220 3 4 200 3 4 200 3 4 200 3 4 200 3 4 200 3 4 200 3 4 200 3 4 200 3 200 3 4 200 200 200 200 200 200 200	Control Mean SD 7.10 0.7780 3.42 0.7716 4.91 0.0896 0.56 0.3578 7.04 0.8201 1.37 1.1153 2.12 0.1505 2.09 0.0995 2.61 0.3617 2.29 0.0414 2.81 0.1147 2.43 0.1500 2.70 0.1835 -0.86 0.6832 9.19 0.8525 7.14 0.9872 -1.25 0.3305 0.34 0.2243 1.81 0.2803 2.73 0.4154 2.11 0.0755 3.47 2.4617 6.90 0.1040 6.52 0.6235 2.38 0.0272 2.24 0.0438 0.47 0.2874 5.62 0.7440 6.49 0.8110 2.46 0.3416 0.38 0.0999 2.48 0.2999 -0.15 0.0341 7.03 0.3652 5.68 0.8251	Standardised Mean difference	$\begin{array}{c} 1.64\\ 0.33\\ 1.30\\ 0.94\\ 0.28\\ 0.05\\ 1.69\\ 2.95\\ 1.52\\ 0.82\\ 1.43\\ 1.42\\ -0.29\\ 3.19\\ 2.25\\ -0.14\\ 1.90\\ 1.53\\ 2.65\\ 2.69\\ 1.66\\ 0.20\\ 1.65\\ 2.71\\ 1.50\\ 1.76\\ -0.30\\ 1.82\\ 2.68\\ 2.41\\ -0.75\\ 1.93\\ 1.95\\ \end{array}$	$ \begin{bmatrix} 0.80; 2.49 \\ 2.5\% \\ [-0.30; 0.97] 2.8\% \\ [1.16; 1.44] 3.4\% \\ [0.71; 1.18] 3.3\% \\ [-0.22; 0.79] 3.0\% \\ [-0.51; 0.60] 2.9\% \\ [1.39; 1.64] 3.4\% \\ [2.36; 3.53] 2.9\% \\ [1.39; 1.64] 3.4\% \\ [0.55; 1.09] 3.3\% \\ [1.06; 1.81] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [-0.57; -0.01] 3.3\% \\ [2.55; 3.74] 3.0\% \\ [1.96; 2.55] 3.3\% \\ [-0.87; 0.59] 2.7\% \\ [0.91; 2.89] 2.2\% \\ [1.00; 1.81] 3.2\% \\ [1.00; 1.81] 3.2\% \\ [1.02; 1.76] 3.0\% \\ [-0.37; 5.67] 0.6\% \\ [0.38; 5.00] 0.9\% \\ [1.45; 1.88] 3.4\% \\ [-1.41; 1.82] 1.4\% \\ [1.10; 2.20] 3.0\% \\ [2.55; 3.10] 3.2\% \\ [1.56; 1.95] 3.4\% \\ [-0.65; 1.95] 3.4\% \\ [-0.65; 0.06] 3.2\% \\ [1.09; 2.55] 2.7\% \\ [1.09; 2.55] 2.7\% \\ [0.37; 4.98] 0.9\% \\ [1.60; 3.23] 2.5\% \\ [-2.06; 0.56] 1.8\% \\ [0.68; 3.17] 1.9\% \\ [1.14; 2.76] 2.5\% \\ \end{bmatrix}$
Study E_MTAB_4171 E_MTAB_8887 GPL10558 GPL1154 GPL14951 GPL16043 GPL21047 GPL570 GPL571 GPL6244 GPL6440 GPL6947 GPL9052 GSE10143_GPL5474 GSE114783_GPL15491 GSE115018_GPL20115 GSE124535_GPL20795 GSE12469_GPL20301 GSE128274_GPL18573 GSE14520_GPL3921 GSE166163_GPL23126 GSE20140_GPL8461 GSE22058_GPL6793 GSE22405_GPL10553 GSE22405_GPL10553 GSE25097_GPL10687 GSE3294_GPL10399 GSE46444_GPL13369 GSE5048_GPL915 GSE5048_GPL915 GSE55545_GPL15433 GSE5955_GPL16699 GSE59259_GPL367 GSE59259_GPL367 GSE59259_GPL367 GSE59259_GPL367 GSE59259_GPL367 GSE59259_GPL367 GSE59259_GPL367 GSE5045_GPL367 GSE5045_GPL367 GSE5045_GPL367 GSE5045_GPL367 GSE5045_GPL367 GSE5045_GPL367 GSE5045_GPL367 GSE5045_GPL367 GSE5045_GPL367 GSE50764_GPL17077	$\begin{array}{c} 15\\ 233\\ 523\\ 163\\ 93\\ 25\\ 10\\ 48\\ 844\\ 96\\ 66\\ 83\\ 104\\ 60\\ 80\\ 10\\ 12\\ 35\\ 3\\ 4\\ 225\\ 3\\ 3\\ 35\\ 100\\ 24\\ 268\\ 3\\ 6\\ 88\\ 67\\ 4\\ 211\\ 5\\ 8\\ 88\\ 67\\ 4\\ 211\\ 5\\ 8\\ 88\\ 3\\ 3\end{array}$	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953 1.42 0.9520 2.60 0.3531 2.56 0.2012 3.46 0.6503 2.37 0.1487 3.09 0.2588 2.69 0.2079 2.64 0.1995 0.03 0.8619 1.23 0.7787 4.69 1.1976 2.38 0.2172 4.00 1.5910 7.29 0.3119 8.70 0.3930 2.44 0.1550 2.89 0.3500 8.32 0.8750 6.23 0.8834 2.89 0.2135 -0.17 0.0174 8.51 0.9276 4.82 0.511 -0.14 1.602	Total 15 17 403 140 18 25 10 48 25 131 75 82 97 60 307 26 60 307 26 12 35 3 4 200 37 26 12 3 3 4 220 3 6 6 8 2 240 3 6 8 2 200 3 6 8 2 200 3 6 8 2 200 3 6 8 2 200 3 6 8 2 200 3 6 8 8 8 8 8 8 8 8 8 8 8 8 8	Control Mean SD 7.10 0.7780 3.42 0.7716 4.91 0.0896 0.56 0.3578 7.04 0.8820 1.37 1.1153 2.12 0.1505 2.09 0.0995 2.61 0.3617 2.29 0.0414 2.81 0.1147 2.43 0.1500 2.70 0.1835 -0.86 0.6832 9.19 0.8525 7.14 0.9872 1.25 0.3305 0.34 0.2243 1.81 0.2803 2.73 0.4156 3.47 2.4617 6.90 0.1040 6.52 0.6235 2.38 0.0272 2.24 0.0438 0.47 0.2874 5.62 0.7440 6.52 0.6316 0.38 0.0299 -0.15 0.0341 7.03 0.3652 5.68 0.8251 5.68 0.8251	Standardised Mean difference	$\begin{array}{c} 1.64\\ 0.33\\ 1.30\\ 0.94\\ 0.28\\ 0.05\\ 1.69\\ 2.95\\ 1.52\\ 0.82\\ 1.43\\ 1.42\\ -0.29\\ 3.19\\ 2.25\\ -0.14\\ 1.90\\ 2.25\\ -0.14\\ 1.90\\ 1.53\\ 2.65\\ 2.69\\ 1.66\\ 0.20\\ 1.65\\ 2.71\\ 1.50\\ 1.65\\ 2.71\\ 1.50\\ 1.76\\ -6.04\\ 3.07\\ -0.30\\ 1.82\\ 2.68\\ 2.41\\ -0.75\\ 1.93\\ 1.95\\ 1.35\\ \end{array}$	$ \begin{bmatrix} 0.80; 2.49 \\ 2.5\% \\ [-0.30; 0.97] 2.8\% \\ [-0.16; 0.97] 2.8\% \\ [1.16; 1.44] 3.4\% \\ [0.71; 1.18] 3.3\% \\ [-0.22; 0.79] 3.0\% \\ [-0.51; 0.60] 2.9\% \\ [1.39; 1.64] 3.4\% \\ [2.36; 3.53] 2.9\% \\ [1.39; 1.64] 3.4\% \\ [0.55; 1.09] 3.3\% \\ [1.06; 1.81] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [-0.57; -0.01] 3.3\% \\ [2.55; 3.74] 3.0\% \\ [2.55; 3.74] 3.0\% \\ [2.55; 3.74] 3.0\% \\ [1.96; 2.55] 3.3\% \\ [-0.87; 0.59] 2.7\% \\ [0.91; 2.89] 2.2\% \\ [1.00; 1.81] 3.2\% \\ [1.00; 1.81] 3.2\% \\ [1.00; 2.55] 3.3\% \\ [-0.37; 5.67] 0.6\% \\ [0.38; 5.00] 0.9\% \\ [1.45; 1.88] 3.4\% \\ [-1.41; 1.82] 1.4\% \\ [1.10; 2.20] 3.0\% \\ [2.32; 3.10] 3.2\% \\ [0.86; 2.15] 2.8\% \\ [1.56; 1.95] 3.4\% \\ [-0.01; 12.09] 0.2\% \\ [1.19; 4.94] 1.2\% \\ [-0.65; 0.06] 3.2\% \\ [1.09; 2.55] 2.7\% \\ [0.37; 4.98] 0.9\% \\ [1.60; 3.23] 2.5\% \\ [-2.06; 0.56] 1.8\% \\ [0.68; 3.17] 1.9\% \\ [1.14; 2.76] 2.5\% \\ [1.13; 1.57] 3.4\% \\ \end{tabular}$
Study E_MTAB_4171 E_MTAB_8887 GPL10558 GPL1154 GPL14951 GPL16043 GPL21047 GPL570 GPL570 GPL571 GPL6244 GPL6480 GPL6947 GPL9052 GSE10143_GPL5474 GSE114783_GPL15491 GSE125469_GPL20301 GSE128274_GPL18573 GSE14520_GPL3921 GSE166163_GPL3921 GSE166163_GPL3921 GSE20140_GPL18573 GSE2097_GPL10637 GSE22058_GPL3931 GSE22058_GPL3931 GSE22058_GPL3931 GSE250579_GPL10637 GSE50579_GPL1350 GSE50545_GPL15433 GSE55555_GPL15433 GSE59259_GPL3451 GSE502_GPL96 GSE5032_GPL96	$\begin{array}{c} 15\\ 233\\ 523\\ 163\\ 93\\ 25\\ 10\\ 48\\ 844\\ 96\\ 66\\ 83\\ 104\\ 60\\ 80\\ 10\\ 12\\ 35\\ 3\\ 4\\ 225\\ 3\\ 35\\ 100\\ 24\\ 268\\ 3\\ 6\\ 88\\ 67\\ 4\\ 21\\ 5\\ 88\\ 67\\ 4\\ 21\\ 5\\ 88\\ 67\\ 4\\ 21\\ 5\\ 88\\ 228\\ \end{array}$	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953 1.42 0.9520 2.60 0.3531 2.56 0.2012 2.60 0.3531 2.56 0.2012 3.40 0.6503 2.37 0.1487 3.09 0.2558 2.69 0.2079 2.64 0.1995 1.59 0.8383 10.99 0.5571 7.00 0.9955 0.03 0.8619 1.23 0.7787 4.69 1.1976 4.81 0.8515 2.38 0.2172 4.00 1.5910 7.40 0.5501 8.30 0.2171 4.40 0.832 2.44 0.15500 8.32 0.8750 6.23 0.8834 2.89	Total 15 17 403 140 25 10 48 528 131 75 82 97 60 307 26 337 4 200 3 44 2209 3 6 48 10 4 21 5 8 18 168 165 59	Control Mean SD 7.10 0.7780 3.42 0.7716 4.91 0.0896 0.56 0.3578 7.04 0.8820 1.37 1.1153 2.12 0.1505 2.09 0.0995 2.01 0.3617 2.29 0.0414 2.81 0.1147 2.43 0.1500 2.70 0.1835 -0.86 0.6832 9.19 0.8525 7.14 0.9872 -1.25 0.3305 0.34 0.2243 1.81 0.2803 2.73 0.4154 2.11 0.0755 3.47 2.4617 6.90 0.104 6.52 0.6235 2.38 0.0272 2.24 0.0438 0.47 0.2874 5.62 0.7440 6.49 0.8110 2.46 0.3416 0.38 0.0999 2.48 0.2099 -0.15 0.0341 7.03 0.3655 5.68 0.8251 4.24 0.1528	Standardised Mean difference	$\begin{array}{c} 1.64\\ 0.33\\ 1.30\\ 0.94\\ 0.28\\ 0.05\\ 1.69\\ 2.95\\ 1.52\\ 0.82\\ -0.29\\ 3.19\\ 2.25\\ -0.14\\ 1.90\\ 1.53\\ 2.65\\ 2.69\\ 1.66\\ 0.20\\ 1.65\\ 2.71\\ 1.50\\ 1.55\\ 2.71\\ 1.50\\ 1.66\\ 0.20\\ 1.65\\ 2.71\\ 1.50\\ 1.66\\ 0.20\\ 1.65\\ 2.71\\ 1.50\\ 1.65\\ 2.71\\ 1.50\\ 1.65\\ 2.71\\ 1.50\\ 1.55\\ 2.11\\ 2.04\\ \end{array}$	$ \begin{bmatrix} 0.80; 2.49 \\ 2.5\% \\ [-0.30; 0.97] 2.8\% \\ [1.16; 1.44] 3.4\% \\ [0.71; 1.18] 3.3\% \\ [-0.22; 0.79] 3.0\% \\ [-0.51; 0.60] 2.9\% \\ [1.39; 1.66] 2.9\% \\ [2.36; 3.53] 2.9\% \\ [1.39; 1.64] 3.4\% \\ [0.55; 1.09] 3.3\% \\ [1.06; 1.81] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [-0.57; -0.01] 3.3\% \\ [1.06; 1.81] 3.2\% \\ [-0.57; -0.01] 3.3\% \\ [1.96; 2.55] 3.3\% \\ [-0.87; 0.59] 2.7\% \\ [0.91; 2.89] 2.2\% \\ [1.00; 2.07] 3.0\% \\ [-0.37; 5.67] 0.6\% \\ [0.38; 5.00] 0.9\% \\ [1.45; 1.88] 3.4\% \\ [-1.41; 1.82] 1.4\% \\ [1.10; 2.20] 3.0\% \\ [1.26; 2.15] 2.8\% \\ [1.156; 1.95] 3.4\% \\ [-0.65; 0.06] 3.2\% \\ [1.56; 1.95] 3.4\% \\ [-0.65; 0.06] 3.2\% \\ [1.09; 2.55] 2.7\% \\ [1.37; 4.98] 0.9\% \\ [1.60; 3.23] 2.5\% \\ [-2.06; 0.56] 1.8\% \\ [0.68; 3.17] 1.9\% \\ [1.14; 2.76] 2.5\% \\ [1.13; 1.57] 3.4\% \\ [0.21; 4.01] 1.1\% \\ [1.60; 2.48] 3.1\% \\ \end{bmatrix}$
Study E_MTAB_4171 E_MTAB_8887 GPL10558 GPL11154 GPL10558 GPL11154 GPL14951 GPL21047 GPL575 GPL576 GPL6947 GPL9052 GSE10143_GPL5474 GSE10143_GPL20115 GSE10143_GPL20155 GSE124535_GPL20795 GSE124535_GPL20795 GSE1245469_GPL20301 GSE124535_GPL20795 GSE1245469_GPL20301 GSE1245469_GPL20301 GSE1245469_GPL20301 GSE124520_GPL3921 GSE166163_GPL31266 GSE2040_GPL18461 GSE22058_GPL6793 GSE220597_GPL10687 GSE32997_GPL10687 GSE50579_GPL14550 GSE50579_GPL14550 GSE55048_GPL9115 GSE55048_GPL1369 GSE55048_GPL13675 GSE55059_GPL18451 GSE63898_GPL13667 GSE63898_GPL13667 GSE63898_GPL13667 GSE631_GPL17077 GSE7631_GPL17586	$\begin{array}{c} 15\\ 233\\ 523\\ 163\\ 93\\ 25\\ 10\\ 48\\ 844\\ 96\\ 66\\ 83\\ 104\\ 60\\ 80\\ 10\\ 12\\ 35\\ 3\\ 4\\ 225\\ 3\\ 35\\ 100\\ 24\\ 268\\ 3\\ 6\\ 88\\ 67\\ 4\\ 11\\ 5\\ 8\\ 18\\ 228\\ 3\\ 62\\ 371 \end{array}$	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953 1.42 0.9520 2.60 0.3531 2.56 0.2012 3.46 0.6503 2.37 0.1487 3.09 0.2558 2.69 0.2079 2.64 0.1995 1.59 0.8383 10.99 0.5571 7.00 0.9955 0.03 0.8619 1.23 0.7787 4.69 1.1976 4.81 0.8515 2.38 0.2172 4.00 1.5910 8.70 0.9390 2.48 0.0875 2.44 0.15500 8.32 0.8750 6.23 0.8844 2.89 0.2171 1.44 0.4793 3.00 0.2135 -0.17	Total 15 17 403 140 25 10 48 528 131 75 82 97 60 307 26 337 4 200 3 44 2209 3 6 48 10 4 21 5 8 18 168 165 59	Control Mean SD 7.10 0.7780 3.42 0.7716 4.91 0.0896 0.56 0.3578 7.04 0.8820 1.37 1.1153 2.12 0.1505 2.09 0.0995 2.61 0.3617 2.29 0.0414 2.81 0.1147 2.43 0.1500 2.70 0.1835 -0.86 0.6832 9.19 0.8525 7.14 0.9872 -1.25 0.3305 0.34 0.2243 1.81 0.2803 2.73 0.4154 2.11 0.0755 3.47 2.4617 6.90 0.1040 6.52 0.6235 2.38 0.0272 2.38 0.0272 2.38 0.0272 2.38 0.0274 0.49 0.8110 2.46 0.3416 0.38 0.0999 2.46 0.3416 0.3652 5.68 0.8251 4.24 0.1528 -1.85 0.4676 2.16 0.0389	Standardised Mean difference	$\begin{array}{c} 1.64\\ 0.33\\ 1.30\\ 0.94\\ 0.28\\ 0.05\\ 1.69\\ 2.95\\ 1.52\\ 0.82\\ 1.43\\ 1.42\\ -0.29\\ 3.19\\ 2.25\\ -0.14\\ 1.90\\ 1.53\\ 2.65\\ 2.69\\ 1.53\\ 2.65\\ 2.71\\ 1.50\\ 1.76\\ -0.30\\ 1.82\\ 2.68\\ 2.41\\ -0.75\\ 1.93\\ 1.95\\ 1.35\\ 2.12\\ 1.93\\ 1.95\\ 1.35\\ 2.12\\ 1.25\\ 1.25\\ 1.35\\ 2.12\\ 1.25\\ 1$	$ \begin{bmatrix} 0.80; 2.49 \\ 2.5\% \\ [-0.30; 0.97] 2.8\% \\ [-0.16; 0.97] 2.8\% \\ [1.16; 1.44] 3.4\% \\ [0.71; 1.18] 3.3\% \\ [-0.22; 0.79] 3.0\% \\ [-0.51; 0.60] 2.9\% \\ [0.63; 2.74] 2.1\% \\ [2.36; 3.53] 2.9\% \\ [1.39; 1.64] 3.4\% \\ [0.55; 1.09] 3.3\% \\ [1.06; 1.81] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [-0.57; -0.01] 3.3\% \\ [2.65; 3.74] 3.0\% \\ [2.65; 3.74] 3.0\% \\ [2.65; 3.74] 3.0\% \\ [2.65; 3.74] 3.0\% \\ [2.65; 3.74] 3.0\% \\ [1.96; 2.55] 3.3\% \\ [-0.87; 0.59] 2.7\% \\ [0.91; 2.89] 2.2\% \\ [1.00; 2.07] 3.0\% \\ [0.38; 5.00] 0.9\% \\ [1.45; 1.88] 3.4\% \\ [-1.41; 1.82] 1.4\% \\ [1.10; 2.20] 3.0\% \\ [2.32; 3.10] 3.2\% \\ [1.56; 1.95] 3.4\% \\ [-0.01; 12.09] 0.2\% \\ [1.19; 4.94] 1.2\% \\ [0.65; 0.06] 3.2\% \\ [1.60; 3.23] 2.5\% \\ [-2.06; 0.56] 1.8\% \\ [0.68; 3.17] 1.9\% \\ [1.14; 2.76] 2.5\% \\ [1.13; 1.57] 3.4\% \\ [0.21; 4.01] 1.1\% \\ \end{bmatrix}$
Study E_MTAB_4171 E_MTAB_8887 GPL10558 GPL1154 GPL14951 GPL16043 GPL21047 GPL570 GPL571 GPL570 GPL571 GPL6244 GPL6480 GPL6947 GPL9052 GSE10143_GPL5474 GSE115018_GPL20115 GSE125469_GPL20301 GSE128274_GPL18573 GSE14520_GPL3921 GSE166163 GPL3921 GSE126163 GPL3921 GSE2040_GPL48513 GSE2097_GPL10687 GSE3294_GPL10553 GSE25079_GPL10687 GSE33294_GPL10999 GSE46444_GPL13369 GSE50579_GPL4450 GSE55545_GPL5433 GSE5555_GPL6691 GSE59259_GPL8451 GSE5052_GPL693 GSE59259_GPL18451 GSE56454_GPL15433 GSE5755_GPL6693 GSE59259_GPL8451 GSE5052_GPL6693 GSE59259_GPL8451 GSE5052_GPL6693 GSE59259_GPL8451 GSE5052_GPL6693 GSE59259_GPL8451 GSE5052_GPL6693 GSE5755_GPL764 GSE775 GSE7764_GPL777 GSE7631_GPL7786 TCGA_GTEx_liver	15 233 163 93 2523 10 48 844 96 66 83 104 60 80 10 12 35 3 4 4 225 3 3 5 100 24 268 3 3 5 100 24 268 3 6 6 88 67 4 21 5 8 8 82 225 3 3 35 10 10 80 10 10 10 80 10 10 80 10 10 80 10 10 80 10 10 80 10 10 80 10 10 80 10 10 80 10 10 80 10 10 80 10 10 80 10 10 10 80 10 10 10 80 10 10 10 80 10 10 10 10 10 10 10 10 10 10 10 10 10	Mean SD 8.48 0.8570 3.68 0.7774 5.16 0.2469 1.11 0.7271 7.24 0.6953 1.42 0.9520 2.60 0.3531 2.56 0.2012 3.40 0.6503 2.37 0.1487 3.09 0.2558 2.69 0.2079 2.64 0.1995 1.59 0.8383 10.99 0.5571 7.00 0.9955 0.03 0.8619 1.23 0.7787 4.69 1.1976 4.81 0.8515 2.38 0.2172 4.00 1.5910 8.70 0.9390 2.48 0.8750 6.23 0.8844 2.89 0.2171 1.44 0.4793 3.00 0.2135 -0.17 0.0174 8.51 0.9571 -0.17	Total 15 17 403 140 18 25 10 48 25 131 75 82 97 60 307 26 3 3 4 220 3 3 4 220 3 6 4 220 3 4 220 3 6 4 220 3 26 27 26 28 20 3 26 27 26 28 20 3 26 27 26 28 20 3 4 200 3 26 27 26 28 20 20 3 26 20 20 20 20 20 20 20 20 20 20	Control Mean SD 7.10 0.7780 3.42 0.7716 4.91 0.0896 0.56 0.3578 7.04 0.8820 1.37 1.1153 2.12 0.1505 2.09 0.0995 2.61 0.3617 2.29 0.0414 2.81 0.1147 2.43 0.1500 2.70 0.1835 -0.86 0.6832 9.19 0.8525 7.14 0.9872 -1.25 0.3305 0.34 0.2243 1.81 0.2803 2.73 0.4154 2.11 0.0755 3.47 2.4617 6.90 0.1040 6.52 0.6235 2.38 0.0272 2.38 0.0272 2.38 0.0272 2.38 0.0274 0.49 0.8110 2.46 0.3416 0.38 0.0999 2.46 0.3416 0.3652 5.68 0.8251 4.24 0.1528 -1.85 0.4676 2.16 0.0389	Standardised Mean difference	$\begin{array}{c} 1.64\\ 0.33\\ 1.30\\ 0.94\\ 0.28\\ 0.05\\ 1.69\\ 2.95\\ 1.52\\ 0.82\\ 1.43\\ 1.42\\ -0.29\\ 3.19\\ 2.25\\ -0.14\\ 1.90\\ 1.53\\ 2.65\\ 2.69\\ 1.53\\ 2.65\\ 2.71\\ 1.50\\ 1.76\\ -0.30\\ 1.82\\ 2.68\\ 2.41\\ -0.75\\ 1.93\\ 1.95\\ 1.35\\ 2.12\\ 1.93\\ 1.95\\ 1.35\\ 2.12\\ 1.25\\ 1.25\\ 1.35\\ 2.12\\ 1.25\\ 1$	$ \begin{bmatrix} 0.80; 2.49 \\ 2.5\% \\ [-0.30; 0.97] 2.8\% \\ [1.16; 1.44] 3.4\% \\ [0.71; 1.18] 3.3\% \\ [-0.22; 0.79] 3.0\% \\ [-0.51; 0.60] 2.9\% \\ [1.39; 1.64] 3.4\% \\ [2.36; 3.53] 2.9\% \\ [1.39; 1.64] 3.4\% \\ [0.55; 1.09] 3.3\% \\ [1.06; 1.81] 3.2\% \\ [1.07; 1.76] 3.2\% \\ [-0.57; -0.01] 3.3\% \\ [1.06; 1.81] 3.2\% \\ [-0.57; -0.01] 3.3\% \\ [1.06; 1.81] 3.2\% \\ [-0.57; 0.59] 2.7\% \\ [0.91; 2.89] 2.2\% \\ [1.00; 2.07] 3.0\% \\ [-0.37; 5.67] 0.6\% \\ [0.38; 5.00] 0.9\% \\ [1.45; 1.88] 3.4\% \\ [-1.41; 1.82] 1.4\% \\ [1.10; 2.20] 3.0\% \\ [2.32; 3.10] 3.2\% \\ [0.36; 2.15] 2.8\% \\ [1.56; 1.95] 3.4\% \\ [-0.65; 0.06] 3.2\% \\ [1.9; 4.94] 1.2\% \\ [-0.65; 0.06] 3.2\% \\ [1.09; 2.55] 2.7\% \\ [0.37; 4.98] 0.9\% \\ [1.16; 3.23] 2.5\% \\ [-2.06; 0.56] 1.8\% \\ [0.68; 3.17] 1.9\% \\ [1.14; 2.76] 2.5\% \\ [1.131; 1.57] 3.4\% \\ [0.21; 4.01] 1.1\% \\ [1.93; 2.31] 3.4\% \\ [1.93; 2.31] 3.4\% \\ [1.93; 2.31] 3.4\% \\ [1.93; 2.31] 3.4\% \\ [1.93; 2.31] 3.4\% \\ [1.93] 2$

E						ТРХ2			
			imenta		Control	Standardised			
Study	Total	Mean	SD	Total	Mean SD	Mean difference	SMD	95%CI	Weight
E_MTAB_4171	15	10.26	1.0168	15	8.41 0.7803	主	1.99	1.09; 2.88]	2.2%
E_MTAB_8887	23		1.5233		3.89 0.8831			0.46; 1.82]	
GPL11154	163		1.0821		1.19 0.6241	*		0.97; 1.46]	
GPL14951	93		0.9911	18	7.84 0.9351			0.46; 1.50]	
GPL16043	25		1.4966		1.26 1.8764			-0.45; 0.66	
GPL16791	79		0.9661		3.89 0.5981	Ti		[1.56; 2.32]	
GPL21047	10		0.1612		3.18 0.1390			0.90; 3.15]	
GPL5175	48		0.1365		2.73 0.1127			2.55; 3.76	
GPL570	844		0.5684		3.68 0.3988			1.37; 1.62	
GPL571	96		0.2371		2.57 0.1021	1		0.32; 0.85]	
GPL6244	66		0.2807		3.11 0.1468	I ∔		1.21; 1.97	
GPL6480	83		0.2020		2.95 0.1400			0.72; 1.37	
GPL6947	104		0.1574		2.90 0.0668			1.31; 1.95]	
GPL9052	60		1.0233		0.51 0.7903	I +		2.55; 3.62	
GSE10143 GPL5474	80		0.2943		11.01 1.1416			1.56; 2.11	
GSE115018 GPL20115	12		0.6863		0.04 0.6861			0.87; 2.85	
GSE124535_GPL20795	35		1.2325		1.11 0.5733			1.07; 2.16]	
GSE125469 GPL20301	3		0.8238		2.65 0.9015			-0.25; 7.13	
GSE128274_GPL18573	4		1.1068		2.82 0.2946			0.56; 5.67]	
GSE14520 GPL3921	225		0.2184		2.48 0.0815	÷		1.98; 2.45	
GSE166163 GPL23126	3		2.1003		4.48 2.2287	<u></u> ;		-1.53; 1.68	
GSE20140_GPL18461	35		0.7116		6.99 0.2617	T-		[1.14; 2.25]	
GSE22058 GPL6793	100		1.0158	97	7.67 0.5869			1.98; 2.70]	
GSE22405_GPL10553	24		0.1083		2.90 0.0536			0.44; 1.66]	
GSE25097 GPL10687	268		0.2530		2.37 0.0556			1.63; 2.02	
GSE33294 GPL10999	3		0.4397		0.97 0.3486			0.08; 14.78	
GSE46408_GPL4133	6		0.8964		6.87 0.6726			1.08; 4.69	
GSE46444 GPL13369	88		1.3515		7.25 1.6778	+		-0.25; 0.45	
GSE50579 GPL14550	67	3.15	0.2460	10	2.73 0.1623	Te		1.02; 2.46	
GSE54238 GPL16955	26	9.44	1.1970	30	6.76 1.0613			1.66; 3.04	
GSE55048 GPL9115	4	2.73	0.9787	4	0.76 0.2108			0.25; 4.58	
GSE56545 GPL15433	21		0.1940		3.00 0.1356	÷		0.79; 2.17	
GSE57555 GPL16699	5		0.0797		-0.14 0.0290			-1.09; 1.40	
GSE59259_GPL18451	8		1.1815	8	8.83 1.0890			0.23; 2.46	
GSE60502 GPL96	18	9.41	0.9929	18	7.18 0.8902		2.30	1.44; 3.17	2.3%
GSE63898 GPL13667	228	6.25	1.1067	168	4.95 0.3327		1.50	1.27; 1.72	3.6%
GSE67764_GPL17077	3	0.08	1.3521	6	-1.92 0.3722			0.29; 4.22]	
GSE76311_GPL17586	62	2.98	0.1768	59	2.68 0.0633			1.82; 2.74]	
TCGA_GTEx_liver	371		1.2066		1.91 0.8761			1.79; 2.17]	
Random effects mode	al 340	8		3014		· · · · · · · · · · · · · · · · · · ·	1.64[1.43; 1.85	j] 100.0%
Heterogeneity: $I^2 = 89\%$, $\tau^2 = 0.2991$, $P < 0.01$						-10 -5 0 5 10			
					DOI: 1	10.5306/wjco.v15.i1.62 Co p	oyright (©The Autho	r(s) 2024.

Figure 7 The expression of five key genes in hepatocellular carcinoma. A-E: The expression level of the five key genes in hepatocellular carcinoma (HCC) samples via the integration of all of the included HCC samples. DLGAP5: DLG associated protein 5; KIF20A: Kinesin family member 20A; ASPM: Assembly factor for spindle microtubules; KIF11: Kinesin family member 11; TPX2: TPX2 microtubule nucleation factor; SD: Standard deviation; SMD: Standard mean difference; CI: Confidence interval.

ScRNA analysis and AUCell

The dataset GSE103867 satisfied our requirements and was obtained for scRNA analysis. After quality control, a total of 3363 cells from HCC samples were identified. Four cell types were identified: hepatocytes, embryonic stem cells, T cells and B cells (Figure 11A). The expression level of five key genes in the four cell types is shown in Figures 11B and C. The AUCell R package was used for determining the TACE refractoriness-related activity in each cell line (Figure 11D). TACE refractoriness-related genes were mainly active in hepatocytes and embryonic stem cells (Figure 11E).

Prediction of cell–cell communication

As shown in Figure 12A-F, hepatocytes as providers of ligands and embryonic stem cells as the providers of receptors had the highest interaction strength. When hepatocytes expressed ligands and embryonic stem cells provided the corresponding receptors, some ligand-receptor pairs like MDK-SDC2 and MDK-NCL had the greatest communication probability of accomplishing cell-cell communication (Figure 12G).

Immune landscape exploration for refractory TACE-treated HCC

TACE non-responders had a higher level of infiltration of follicular helper T cells, macrophages M0 and active mast cells than TACE responders. While TACE non-responders were associated with a lower level of infiltration of active memory CD4⁺ T cells, macrophages M1 and M2 macrophages (Figure 13A). The analysis of the connection between the expression of key genes and the infiltration of 22 kinds of immune cell in CIBERSORT algorithm was performed (Figure 13B-F). The correlation among hepatocytes, phenotypes of T cells and phenotypes of B cells was computed using the xCell algorithm (Figure 14A). TACE non-responders were calculated as having lower stroma and microenvironment scores (Figure 14B).

The potential therapeutic drugs discovery

There were 27 kinds of drugs used in the treatment of HCC in the pRRophetic R package. The IC₅₀ values of the 27 chemotherapeutics were compared between TACE non-responders and TACE responders. Five chemotherapeutics






Figure 8 The protein expression of the key genes in non-hepatocellular carcinoma and hepatocellular carcinoma tissues via immunohistochemistry derived from The Human Protein Atlas database. The immunohistochemistry for protein expression of key-gene assembly factor for spindle microtubules was deficient in THPA database. DLGAP5: DLG associated protein 5; KIF20A: Kinesin family member 20A; KIF11: Kinesin family member 11; TPX2: TPX2 microtubule nucleation factor.


(CCT007093, Dasatinib, Erlotinib, Bortezomib and Lapatinib) had the potential for reversing TACE non-response (Figure 15).

DISCUSSION

In this study, we have achieved the following targets: (1) Five key genes (DLGAP5, KIF20A, ASPM, KIF11 and TPX2) were identified among TACE refractoriness-related genes and all overexpressed in the TACE non-responders group and the HCC group; (2) a higher expression of five key genes predicted a worse overall survival (OS) probability in HCC, and TPX2 was considered to be an independent prognostic factor in HCC; (3) cell cycle pathway was likely to play a role in




Raishideng® WJCO https://www.wjgnet.com



WJCO https://www.wjgnet.com

Srishideng®



DOI: 10.5306/wjco.v15.i1.62 Copyright ©The Author(s) 2024.

Figure 9 The Kaplan-Meier curve analysis. A: The multivariate analysis of five key genes; B–F: Survival curves for the five key genes. DLGAP5: DLG associated protein 5; KIF20A: kinesin family member 20A; ASPM: Assembly factor for spindle microtubules; KIF11: Kinesin family member 11; TPX2: TPX2 microtubule nucleation factor; HR: Hazard ratio; CI: Confidence interval.

resisting TACE therapy with enrichment analysis using TACE refractoriness-related genes; (4) four cell types, hepatocytes, embryonic stem cells, T cells and B cells, were identified in HCC samples *via* scRNA sequencing analysis, and hepatocytes and embryonic stem cells were seen as possibly promoting TACE refractoriness *via* AUCell and CellChat analysis; (5) the immune environment landscapes of the TACE non-response group and the TACE response group were revealed; (6) some compounds, like CCT007093, Dasatinib, Erlotinib, Bortezomib and Lapatinib, might be effective for the TACE non-response group according to drug-sensitivity analysis.

Some advanced imaging techniques have been reported as predicting the therapeutic response of TACE in HCC through the detection of liver hemodynamics, water molecule diffusion capacity, metabolic changes and blood-oxygen level[26]. One study found that the blood-oxygen level significantly decreased in the cancerous region of 30 HCC patients after receiving TACE but saw no notable changes in 30 healthy volunteers[27]. TACE creates a hypoxic microenvironment due to arterial embolisation, which contributes to a surge in the vascular endothelial growth factor, p53, which enlarges tumour size and decreases the survival rate[28,29]. Cheng *et al*[30] found that TPX2, as one of the hypoxia-related genes, was obviously and clearly expressed in a high-risk HCC group and participated in TACE refractoriness. Our study has identified TPX2 as a key gene for possibly inducing TACE refractoriness.

On the basis of some studies, autophagy may be a significant mechanism mediating the therapeutic efficacy of TACE in HCC. Autophagy protects the cancer cells from abominable conditions such as hypoxia, starvation and cell apoptosis induced by chemotherapy and enhances the cancer cells' resistance to hypoxic and chemotherapy[27]. Mao *et al*[29] demonstrated that apoptosis-stimulating p53 protein 2 (ASPP2) was low-expression in recurrent HCC patients after TACE treatment and confirmed that ASPP2, as a co-expression factor of the cancer suppressor p53, was responsible for decreasing the autophagy maker Beclin-1. Gao *et al*[31] concluded that TACE in combination with the autophagic inhibitor chloroquine shown to be more efficient at curing tumours in rabbit liver than TACE alone.

Further investigation of research showed that MicroRNA (miRNA) also has a substantial effect on the low therapeutic efficacy of TACE in HCC. Wei *et al*[20] found that down-regulated miR-125b was related to the recurrence of HCC after TACE treatment. They concluded that the low miR-125b expression attenuated the HIF1 α translation to activate the HIF1 α /pAKT loop and block the autocrine HIF1 α /platelet-derived growth factor β (PDGF β)/pAKT/HIF1 α loop of HIF1 α translation by targeting PDGF β . Tumour-initiating cells (T-ICs) or cancer stem cells (CSCs) are a phenotype of cancer cells with a self-renewal and tumorigenesis faculty[32]. T-ICs and CSCs are connected to cancer proliferation and anti-cancer therapy resistance[33]. Clinical cohort analysis indicates that HCC patients with high miR-186 expression benefit from TACE[34]. Yao *et al*[34] found that a miR-186 knockdown led to the expansion of CSCs while a high expression of miR-186 inhibited the process. Additionally, other miRNA, like miR-26a, miR-107 and miR-106, were differentially expressed between TACE non-responders and TACE responders, and their differential expression was correlated with OS and progression-free survival[35].

Consistent with the description above, the engagement of T-IC and CSCs is another critical mechanism in the resistance of TACE in HCC. Zeng *et al*[36] stated that the CSC makers like epithelial cell adhesion molecule had a higher expression in TACE-treated specimens than non-TACE specimens, which indicated that HCC with abundant CSCs phenotype had a high risk of recurrence after TACE treatment. Subsequently, Xiang *et al*[37] explained that a low expression of Srchomology 2 domain-containing phosphatase 2 (Shp2) was favourable for a high therapeutic effect from TACE. As for the mechanism, they found that Shp2 appeared in sorted epithelial cell adhesion molecule-positive or clusters of differen-

WJCO https://www.wjgnet.com




Figure 10 Enrichment analysis. A: Gene Ontology analysis of transcatheter arterial chemoembolisation (TACE) refractoriness-related genes. The top-five biological processes, the top-five cellular components, and the top-five molecular functions are shown; B: The Kyoto Encyclopaedia of Genes and Genomes and Reactome pathways of TACE refractoriness-related genes.

tiation 133-positive liver CSCs and in CSC-enriched hepatoma spheroids from patients, and that a high expression of Shp2 promoted the proliferation of liver CSCs by enhancing an accumulation of β -catenin[37]. Some transcription factors of embryonic stem cells had the ability to regulate the CSCs in pancreatic cancer[38]. Zhou *et al*[39] identified some potential methylation-related genes that become enriched in the embryonic stem cell pathway to characterise HCC, which indicated embryonic stem cells might play a role in HCC progression. The derivatives of embryonic stem cells were able to generate hepatocytes[40]. Hepatocytes were found to create a profound metabolic rewiring when preparing to proliferate in HCC[41]. However, there was little evidence to show the function of hepatocytes and embryonic stem cells




Figure 11 Single-cell RNA sequencing analysis and AUCell. A: Uniform manifold approximation and projection (UMAP) plot showing four cell types in hepatocellular carcinoma samples; B: Violin plots showing the expression level of five key genes in four cell types. C: Expression level of five key genes in four cell types were drawn on UMAP; D: AUCell score distribution curves of 112 transcatheter arterial chemoembolisation (TACE) refractoriness-related genes; E: Scatter plot showing the distribution of AUCell scores in 112 TACE refractoriness-related genes. DLGAP5: DLG associated protein 5; KIF20A: Kinesin family member 20A;

Janishideng® WJCO | https://www.wjgnet.com

ASPM: Assembly factor for spindle microtubules; KIF11: Kinesin family member 11; TPX2: TPX2 microtubule nucleation factor; AUC: Area under the curve.





Figure 12 Cell-cell communication. A and B: The aggregated intercellular communication between any two cell groups. The colours of the periphery circle referred to one cell group and the vertex of periphery circle represented the numbers of cells. The cells in the starting site of edge expressed ligand and the cells the

arrow pointed in expressed receptor. The thickness of the line signified the numbers of ligand-receptor pairs, and the thicker the line meant more ligand-receptor pairs; B: The thickness of edge represented the interaction strength of any two cell groups. The thicker the edge was, the bigger the interaction strength; C-F: The intercellular communication of each cell group. Hepatocytes providing ligands had strongest communication with embryonic stem cells that expressed receptors; G: The identification of ligand-receptor pairs between hepatocytes and embryonic stem cells. (Ligands provider)-(receptors provider).





Zaishideng® WJCO https://www.wjgnet.com





Figure 13 Immune infiltration analysis. A: The immune landscape of 22 kinds of immune cells between transcatheter arterial chemoembolisation (TACE) non-

Raishideng® WJCO | https://www.wjgnet.com

responders and TACE responders using CIBERSORT algorithm. (${}^{a}P < 0.05$, ${}^{b}P < 0.01$, ${}^{c}P < 0.001$, ${}^{d}P < 0.0001$); B-F: The relationship between expression of five key genes and the infiltration of 22 kinds of immune cells in TACE non-responders group. DLGAP5: DLG associated protein 5; KIF20A: Kinesin family member 20A; ASPM: Assembly factor for spindle microtubules; KIF11: Kinesin family member 11; TPX2: TPX2 microtubule nucleation factor; AUC: Area under the curve.







Figure 14 xCell immune infiltration analysis. A: The correlation between hepatocytes, phenotypes of T cells and phenotypes of B cells by xCell algorithm; B: The comparison of immune, stromal and microenvironment score between transcatheter arterial chemoembolisation (TACE) non-responders and TACE responders by xCell algorithm.

Baishidena® WJCO | https://www.wjgnet.com



Baishideng®

WJCO https://www.wjgnet.com




Figure 15 The prediction of potential drugs for refractory transcatheter arterial chemoembolisation treated hepatocellular carcinoma. IC₅₀: Half maximal inhibitory concentration.

in TACE refractoriness.

The metabolic process is considered to play a part in the occurrence of TACE refractoriness in HCC. Aberrant glutamine metabolism (GM) is involved in tumorigenesis and poor prognosis[42,43]. Ying *et al*[43] employed 41 GM-associated genes to construct a transcriptome-based approach named 'GM score' and validated it using two independent HCC cohorts. The results showed that a high GM score had a positive correlation with a slim OS of HCC patients after TACE treatment. Therefore, it is plausible that the metabolic process and immune infiltration level may be connected to TACE refractoriness in HCC.

In this study, five key genes have been identified as being highly correlated with TACE refractoriness in HCC, and its potential mechanisms have been discussed. However, some limitations exist in this study. Firstly, although the five key genes (DLGAP5, KIF20A, ASPM, KIF11 and TPX2) were verified as being associated with TACE refractoriness, the clinical applicability of these genes requires more cases as confirmation due to the limited number of TACE-treated patients in this study and the heterogeneity in the diagnosis. Secondly, due to insufficient samples of HCC cells and

Raishideng® WJCO https://www.wjgnet.com

stroma treated by TACE, we have no scope for the further validation of the five key genes. Thirdly, the results of the AUCell analysis that TACE refractoriness-related genes were mainly active in hepatocytes and embryonic stem cells require further verification due to only one cell reaching the AUC threshold of TACE refractoriness-related genes list. Lastly, the potential mechanisms identified also need further proof through additional vivo and vitro experiments.

CONCLUSION

Five key genes (DLGAP5, KIF20A, ASPM, KIF11 and TPX2) were all up-regulated to facilitate TACE refractoriness. Hepatocytes and embryonic stem cells had intimate intercellular communication and were likely to boost TACE refractoriness. CCT007093, Dasatinib, Erlotinib, Bortezomib and Lapatinib possibly played a curable role in TACE nonresponders.

ARTICLE HIGHLIGHTS

Research background

Transcatheter arterial embolisation (TACE) is a primary therapeutic strategy for hepatocellular carcinoma (HCC) patients in the intermediate and advanced stages. In China, TACE refractoriness is defined as the intrahepatic target lesion that remains in a disease progression state after receiving standardised and refined TACE treatment for three or more times consecutively.

Research motivation

It is essential to identify biomarkers for predicting TACE refractoriness and to explore the potential mechanisms of TACE refractoriness.

Research objectives

The purpose of our study is to identify the key genes associated with TACE refractoriness and investigate the potential mechanisms of TACE refractoriness.

Research methods

The gene expression profile was obtained from the public databases. Weighted gene co-expression network analysis and the cytoHubba plugin were utilised to identify the key genes in TACE refractoriness. Multivariate Cox regression and Kaplan-Meier were employed. ScRNA analysis was used for exploring the potential mechanisms of TACE refractoriness.

Research results

Five key genes (DLGAP5, KIF20A, ASPM, KIF11, and TPX2) were all up-regulated in TACE non-responders, which predicted poor prognosis. TPX2 is recognised as an independent prognostic factor. TACE refractoriness-related genes were mainly active in hepatocytes and embryonic stem cells. Hepatocytes and embryonic stem cells showed strong cellular interactions in HCC.

Research conclusions

Five key genes (DLGAP5, KIF20A, ASPM, KIF11, and TPX2) were identified as being associated with TACE refractoriness. Hepatocytes and embryonic stem cells probably promoted TACE refractoriness.

Research perspectives

More vivo and vitro experiments are essential to elaborate and verify the significance of the key genes and the potential mechanisms involved in TACE refractoriness.

ACKNOWLEDGEMENTS

The authors thank Guangxi Key Laboratory of Medical Pathology for their technical support.

FOOTNOTES

Author contributions: Huang JZ and Li JD took part in data collection, statistical analysis, interpretation and paper drafting; He RQ and Chen G were responsible for study design, statistical analysis guidance and paper correction.

Supported by Guangxi Higher Education Undergraduate Teaching Reform Project, No. 2021JGA142; Guangxi Educational Science Planning Key Project, No. 2022ZJY2791; Guangxi Medical University Education and Teaching Reform Project, No. 2021XJGA02; and



Guangxi Zhuang Autonomous Region Health Commission Self-financed Scientific Research Project, No. Z20201147.

Institutional review board statement: The study did not involve any human or animal related experiments, so no statement of ethics will be provided.

Informed consent statement: The letter is to state that "informed consent" is not apply for our manuscript because the data of this study are from the public database TCGA, GEO and GTEx database.

Conflict-of-interest statement: We have no financial relationships to disclose.

Data sharing statement: The datasets analysed in this study are publicly available in the TCGA (https://portal.gdc.cancer.gov/), GEO (https://www.ncbi.nlm.nih.gov/geo/) and GTEx (https://gtexportal.org/home/) databases.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China

ORCID number: Jie-Zhuang Huang 0009-0006-8471-3826; Jian-Di Li 0000-0001-7050-371X; Gang Chen 0000-0003-2402-2987; Rong-Quan He 0000-0002-7752-2080.

S-Editor: Liu JH L-Editor: A P-Editor: Zhang XD

REFERENCES

- Chen X, Lu Y, Shi X, Han G, Zhang L, Ni C, Zhao J, Gao Y, Wang X. Epidemiological and Clinical Characteristics of Five Rare Pathological 1 Subtypes of Hepatocellular Carcinoma. Front Oncol 2022; 12: 864106 [PMID: 35463333 DOI: 10.3389/fonc.2022.864106]
- Zhang X, Zou H, Chen Y, Zhang H, Tian R, Meng J, Zhu Y, Guo H, Dai E, Zhu B, Liu Z, Jin Y, Li Y, Feng L, Zhuang H, Pan CQ, Li J, Duan 2 Z. The effects of increased dose of hepatitis B vaccine on mother-to-child transmission and immune response for infants born to mothers with chronic hepatitis B infection: a prospective, multicenter, large-sample cohort study. BMC Med 2021; 19: 148 [PMID: 34253217 DOI: 10.1186/s12916-021-02025-11
- Gufler S, Sceboeck R, Schatz C, Haybaeck J. The Translational Bridge between Inflammation and Hepatocarcinogenesis. Cells 2022; 11 3 [PMID: 35159342 DOI: 10.3390/cells11030533]
- Yao J, Liang X, Liu Y, Li S, Zheng M. Trends in Incidence and Prognostic Factors of Two Subtypes of Primary Liver Cancers: A 4 Surveillance, Epidemiology, and End Results-Based Population Study. Cancer Control 2022; 29: 10732748211051548 [PMID: 35147456 DOI: 10.1177/10732748211051548]
- Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, Wang C. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat 5 Rev Gastroenterol Hepatol 2023; 20: 203-222 [PMID: 36369487 DOI: 10.1038/s41575-022-00704-9]
- Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular 6 classification. Adv Cancer Res 2021; 149: 1-61 [PMID: 33579421 DOI: 10.1016/bs.acr.2020.10.001]
- Kim H, Choi B, Mouli SK, Choi H, Harris KR, Kulik LM, Lewandowski RJ, Kim DH. Preclinical Development and Validation of 7 Translational Temperature Sensitive Iodized Oil Emulsion Mediated Transcatheter Arterial Chemo-Immuno-Embolization for the Treatment of Hepatocellular Carcinoma. Adv Healthc Mater 2023; 12: e2300906 [PMID: 37163283 DOI: 10.1002/adhm.202300906]
- Yang Y, Lin K, Liu L, Qian Y, Yang Y, Yuan S, Zhu P, Huang J, Liu F, Gu F, Fu S, Jiang B, Liu H, Pan Z, Lau WY, Zhou W. Impact of 8 preoperative TACE on incidences of microvascular invasion and long-term post-hepatectomy survival in hepatocellular carcinoma patients: A propensity score matching analysis. Cancer Med 2021; 10: 2100-2111 [PMID: 33650288 DOI: 10.1002/cam4.3814]
- 9 Khan AR, Wei X, Xu X. Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides. J Hepatocell Carcinoma 2021; 8: 1089-1115 [PMID: 34522691 DOI: 10.2147/JHC.S318070]
- Hatanaka T, Yata Y, Naganuma A, Kakizaki S. Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial 10 Chemoembolization, Systemic Therapy, and Conversion Therapy. Cancers (Basel) 2023; 15 [PMID: 36980684 DOI: 10.3390/cancers15061798]
- Wang P, Song X, Cao D, Cui K, Wang J, Utpatel K, Shang R, Wang H, Che L, Evert M, Zhao K, Calvisi DF, Chen X. Oncogene-dependent 11 function of BRG1 in hepatocarcinogenesis. Cell Death Dis 2020; 11: 91 [PMID: 32019910 DOI: 10.1038/s41419-020-2289-3]
- Yang S, Pang L, Dai W, Wu S, Ren T, Duan Y, Zheng Y, Bi S, Zhang X, Kong J. Role of Forkhead Box O Proteins in Hepatocellular 12 Carcinoma Biology and Progression (Review). Front Oncol 2021; 11: 667730 [PMID: 34123834 DOI: 10.3389/fonc.2021.667730]
- Reig M, Darnell A, Forner A, Rimola J, Ayuso C, Bruix J. Systemic therapy for hepatocellular carcinoma: the issue of treatment stage 13 migration and registration of progression using the BCLC-refined RECIST. Semin Liver Dis 2014; 34: 444-455 [PMID: 25369306 DOI: 10.1055/s-0034-1394143]
- Liu B, Zhang Y, Chen H, Li W, Tsochatzis E. The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation 14 versus TACE alone for hepatocellular carcinoma. Cochrane Database Syst Rev 2022; 1: CD013345 [PMID: 34981511 DOI: 10.1002/14651858.CD013345.pub2]
- 15 Kosaka Y, Kimura T, Kawaoka T, Ogawa Y, Amioka K, Naruto K, Yoshikawa Y, Kikukawa C, Suehiro Y, Yamaoka K, Ando Y, Uchikawa



S, Morio K, Nakahara T, Murakami E, Takahashi S, Tsuge M, Hiramatsu A, Imamura M, Chosa K, Awai K, Nagata Y, Chayama K, Aikata H. Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein. Liver Cancer 2021; 10: 151-160 [PMID: 33977091 DOI: 10.1159/000513706]

- 16 Núñez KG, Sandow T, Fort D, Hibino M, Wright P, Cohen AJ, Thevenot PT. PD-1 expression in hepatocellular carcinoma predicts liverdirected therapy response and bridge-to-transplant survival. Cancer Immunol Immunother 2022; 71: 1453-1465 [PMID: 34689234 DOI: 10.1007/s00262-021-03087-z]
- Zhao P, Zhao J, Deng Y, Zeng G, Jiang Y, Liao L, Zhang S, Tao Q, Liu Z, Tang X, Tu X, Jiang L, Zhang H, Zheng Y. Application of iron/ 17 barium ferrite/carbon-coated iron nanocrystal composites in transcatheter arterial chemoembolization of hepatocellular carcinoma. J Colloid Interface Sci 2021; 601: 30-41 [PMID: 34058551 DOI: 10.1016/j.jcis.2021.05.102]
- 18 Fako V, Martin SP, Pomyen Y, Budhu A, Chaisaingmongkol J, Franck S, Lee JM, Ng IO, Cheung TT, Wei X, Liu N, Ji J, Zhao L, Liu Z, Jia HL, Tang ZY, Qin LX, Kloeckner R, Marquardt J, Greten T, Wang XW. Gene signature predictive of hepatocellular carcinoma patient response to transarterial chemoembolization. Int J Biol Sci 2019; 15: 2654-2663 [PMID: 31754337 DOI: 10.7150/ijbs.39534]
- 19 Martin SP, Fako V, Dang H, Dominguez DA, Khatib S, Ma L, Wang H, Zheng W, Wang XW. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma. J Exp Clin Cancer Res 2020; 39: 99 [PMID: 32487192 DOI: 10.1186/s13046-020-01605-y]
- Wei X, Zhao L, Ren R, Ji F, Xue S, Zhang J, Liu Z, Ma Z, Wang XW, Wong L, Liu N, Shi J, Guo X, Roessler S, Zheng X, Ji J. MiR-125b 20 Loss Activated HIF1a/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma. Hepatology 2021; 73: 1381-1398 [PMID: 32609900 DOI: 10.1002/hep.31448]
- 21 Myojin Y, Kodama T, Maesaka K, Motooka D, Sato Y, Tanaka S, Abe Y, Ohkawa K, Mita E, Hayashi Y, Hikita H, Sakamori R, Tatsumi T, Taguchi A, Eguchi H, Takehara T. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma. Clin Cancer Res 2021; 27: 1150-1161 [PMID: 33288659 DOI: 10.1158/1078-0432.CCR-20-3382]
- 22 Li X, Duan Y, Hao Y. Identification of super enhancer-associated key genes for prognosis of germinal center B-cell type diffuse large B-cell lymphoma by integrated analysis. BMC Med Genomics 2021; 14: 69 [PMID: 33663517 DOI: 10.1186/s12920-021-00916-z]
- Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan CH, Myung P, Plikus MV, Nie Q. Inference and analysis of cell-cell 23 communication using CellChat. Nat Commun 2021; 12: 1088 [PMID: 33597522 DOI: 10.1038/s41467-021-21246-9]
- 24 Huang J, Chen T, Wang J, Wang Z, Huang S. Weighted gene co-expression network analysis and CIBERSORT screening of key genes related to m6A methylation in Hirschsprung's disease. Front Genet 2023; 14: 1183467 [PMID: 37144136 DOI: 10.3389/fgene.2023.1183467]
- Teng L, Shen L, Zhao W, Wang C, Feng S, Wang Y, Bi Y, Rong S, Shushakova N, Haller H, Chen J, Jiang H. SLAMF8 Participates in Acute 25 Renal Transplant Rejection via TLR4 Pathway on Pro-Inflammatory Macrophages. Front Immunol 2022; 13: 846695 [PMID: 35432371 DOI: 10.3389/fimmu.2022.846695
- Yang K, Zhang XM, Yang L, Xu H, Peng J. Advanced imaging techniques in the therapeutic response of transarterial chemoembolization for 26 hepatocellular carcinoma. World J Gastroenterol 2016; 22: 4835-4847 [PMID: 27239110 DOI: 10.3748/wjg.v22.i20.4835]
- 27 Su H, Yang F, Fu R, Li X, French R, Mose E, Pu X, Trinh B, Kumar A, Liu J, Antonucci L, Todoric J, Liu Y, Hu Y, Diaz-Meco MT, Moscat J, Metallo CM, Lowy AM, Sun B, Karin M. Cancer cells escape autophagy inhibition via NRF2-induced macropinocytosis. Cancer Cell 2021; **39**: 678-693.e11 [PMID: 33740421 DOI: 10.1016/j.ccell.2021.02.016]
- Lin ZH, Jiang JR, Ma XK, Chen J, Li HP, Li X, Wu XY, Huang MS, Lin Q. Prognostic value of serum HIF-1a change following transarterial 28 chemoembolization in hepatocellular carcinoma. Clin Exp Med 2021; 21: 109-120 [PMID: 33037574 DOI: 10.1007/s10238-020-00667-8]
- Mao J, Tan Z, Pan X, Meng F. ASPP2 expression predicts the prognosis of patients with hepatocellular carcinoma after transcatheter arterial 29 chemoembolization. Exp Ther Med 2021; 21: 397 [PMID: 33680119 DOI: 10.3892/etm.2021.9828]
- Cheng X, Li J, Feng L, Feng S, Wu X, Li Y. The role of hypoxia-related genes in TACE-refractory hepatocellular carcinoma: Exploration of 30 prognosis, immunological characteristics and drug resistance based on onco-multi-OMICS approach. Front Pharmacol 2022; 13: 1011033 [PMID: 36225568 DOI: 10.3389/fphar.2022.1011033]
- Gao L, Song JR, Zhao JW, Zhao X, Zhao QD, Sun K, Deng WJ, Li R, Lv G, Cheng HY, Wei LX. Chloroquine promotes the anticancer effect 31 of TACE in a rabbit VX2 Liver tumor model. Int J Biol Sci 2013; 9: 322-330 [PMID: 23569437 DOI: 10.7150/ijbs.5925]
- Sadasivam S, Subramanian R. A perspective on challenges and opportunities in characterizing oral cancer stem cells. Front Biosci (Landmark 32 Ed) 2020; 25: 1011-1021 [PMID: 32114422 DOI: 10.2741/4845]
- Han J, Won M, Kim JH, Jung E, Min K, Jangili P, Kim JS. Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective. Chem 33 Soc Rev 2020; 49: 7856-7878 [PMID: 32633291 DOI: 10.1039/d0cs00379d]
- Yao H, Yang Z, Lou Y, Huang J, Yang P, Jiang W, Chen S. miR-186 Inhibits Liver Cancer Stem Cells Expansion via Targeting PTPN11. 34 Front Oncol 2021; 11: 632976 [PMID: 33816273 DOI: 10.3389/fonc.2021.632976]
- Ali HEA, Emam AA, Zeeneldin AA, Srour R, Tabashy R, El-Desouky ED, Abd Elmageed ZY, Abdel-Wahab AA. Circulating miR-26a, miR-35 106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization. Clin Biochem 2019; 65: 45-52 [PMID: 30653948 DOI: 10.1016/j.clinbiochem.2019.01.002]
- Zeng Z, Ren J, O'Neil M, Zhao J, Bridges B, Cox J, Abdulkarim B, Schmitt TM, Kumer SC, Weinman SA. Impact of stem cell marker 36 expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation. BMC Cancer 2012; 12: 584 [PMID: 23216644 DOI: 10.1186/1471-2407-12-584]
- Xiang D, Cheng Z, Liu H, Wang X, Han T, Sun W, Li X, Yang W, Chen C, Xia M, Liu N, Yin S, Jin G, Lee T, Dong L, Hu H, Wang H, Ding 37 J. Shp2 promotes liver cancer stem cell expansion by augmenting β-catenin signaling and predicts chemotherapeutic response of patients. Hepatology 2017; 65: 1566-1580 [PMID: 28059452 DOI: 10.1002/hep.28919]
- Herreros-Villanueva M, Bujanda L, Billadeau DD, Zhang JS. Embryonic stem cell factors and pancreatic cancer. World J Gastroenterol 38 2014; 20: 2247-2254 [PMID: 24605024 DOI: 10.3748/wjg.v20.i9.2247]
- 39 Zhou S, Li M, Ostrow D, Ruble D, Mascarenhas L, Pawel B, Buckley JD, Triche TJ. Potential methylation-regulated genes and pathways in hepatocellular neoplasm, not otherwise specified. Front Oncol 2022; 12: 952325 [PMID: 36212481 DOI: 10.3389/fonc.2022.952325]
- Mennen RH, Oldenburger MM, Piersma AH. Endoderm and mesoderm derivatives in embryonic stem cell differentiation and their use in 40 developmental toxicity testing. Reprod Toxicol 2022; 107: 44-59 [PMID: 34861400 DOI: 10.1016/j.reprotox.2021.11.009]
- Hall Z, Chiarugi D, Charidemou E, Leslie J, Scott E, Pellegrinet L, Allison M, Mocciaro G, Anstee QM, Evan GI, Hoare M, Vidal-Puig A, 41 Oakley F, Vacca M, Griffin JL. Lipid Remodeling in Hepatocyte Proliferation and Hepatocellular Carcinoma. Hepatology 2021; 73: 1028-1044 [PMID: 32460431 DOI: 10.1002/hep.31391]



WJCO | https://www.wjgnet.com

Huang JZ et al. Key genes associated with TACE refractoriness

- Li B, Cao Y, Meng G, Qian L, Xu T, Yan C, Luo O, Wang S, Wei J, Ding Y, Yu D. Targeting glutaminase 1 attenuates stemness properties in 42 hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway. EBioMedicine 2019; 39: 239-254 [PMID: 30555042 DOI: 10.1016/j.ebiom.2018.11.063]
- 43 Ying L, Cheng M, Lu Y, Tao Q, Chen X, Shen B, Xiong F, Hu Z, Wang D, Li X. Glutamine Metabolism Scoring Predicts Prognosis and Therapeutic Resistance in Hepatocellular Carcinoma. Pathol Oncol Res 2021; 27: 1610075 [PMID: 34992505 DOI: 10.3389/pore.2021.1610075]





Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: office@baishideng.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

